

































Toyama Medical Journal　Vol. 25　No. 1　2014 1
(Received 11 September 2014 / Accepted 17 September 2014)
Department of Behavioral Sciences,　Faculty of Medicine, University of Toyama, Sugitani, Toyama 930-0194, Japan
Present address: Fukui College of Health Sciences, 55-13-1 Egami, Fukui City, Fukui 910-3190, Japan
emotional sensations3). Another paper discusses histori-
cal aspects of the emotion related James-Lange theory4).
　On the other hand, continuity of emotion between 
animals and humans was initially discussed by Charles 
Darwin5). His idea led to a basic emotion theory where 
emotion consists of a limited set of fundamental emo-
tions across species and across cultures. He suggested 
a similarity of facial expression of anger among dogs, 
monkeys and humans, as an example.
　His idea was developed into the basic emotion theo-
ries of Ekman6), Izard7), and Panpsepp8), etc. These ap-
proaches depend on the existence of a small set of dis-
Introduction
　It has been nearly 130 years since William James 
published a seminal paper titled “What is an emotion?”1).
　His hypothesis is well-known as the James-Lange the-
ory which states some emotions are accompanied by 
peripheral bodily change2). For example, fear results as 
an animal encounters a predator which causes an in-
crease in heart rate. His theory stimulated later re-
search into emotions. However, Cannon indicated nega-
tive data to the peripheral hypothesis of the James-
Lange theory, through verifying that surgical separa-
tion of the visceral inputs from the brain did not impair 
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　This paper proposes an evolutionary hierarchical hypothesis that feelings/emotions in humans con-
sist of four sub-systems of emotion based on brain structure, brain functions, brain evolution and 
emotional evolution. Feelings/emotions in humans are composed of primitive emotions, core emotions, 
social emotions/feelings and intellectual feelings, with respect to evolution. Primitive emotions are 
composed of two emotions, well and unwell states, that are elicited by positive and negative reinforcers 
in relation to homeostasis. Core emotions are composed of five basic emotions such as pleasure, anger, 
fear, disgust and acceptance or love, which are strongly related to survival of predator-prey situations, 
and gene competition for sexual selection. Social emotions/feelings are induced by cooperation and 
competition in groups.  Intellectual feelings are separated from social emotions/feeling in humans, and 
are related to functions of a symbiotic and cultural nature. This paper discusses each of the character-
istics and boundary conditions in the brain of these four sub-systems of human feelings/emotions 
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man brain17). Meanwhile, its structures and functions 
would pass through a number of different stages.
　Our idea about the structure and function of the emo-
tions is initially based on the triune brain model of Ma-
cLean’s. It also depends on the functional base model 
from social psychology, which classifies individuals’ in-
teractions with the environment and others into four 
levels; intra-individual, inter-individual, intra-group, and 
inter-group18). This suggests that the experiences of an 
individual’s interactions with their environment and 
others expand through evolution toward larger groups, 
thereby leading to a larger brain. Our hypothesis of 
emotions/feelings consists of four evolutionary sub-sys-
tems (Fig. 1).
　The individual sub-system consists of a single sub-
ject, meaning that the maintenance of one’s body is im-
portant to life. Main functions to support the body in-
clude energy supply, water balance, temperature regu-
lation, and reproduction19). For example, oviparous fish 
lives a primarily solitary life in the sea with little or no 
embryonic development within the mother. Their early 
nervous system might be developed for maintaining a 
full body in a homeostatic condition.
　The second term, inter-individual, including predator 
and partners, means basically coping with others in 
one-to-one relationships. Here surviving among other 
animals requires further evolution of higher processing 
of sensory and motor information, leading to abilities 
such as escaping and defending oneself from predators, 
abilities which are selected for through increased sur-
vival of more environmentally aware individuals. Fur-
thermore, competition for finding and selecting a part-
ner also plays a strong role with respect to competition 
in gene selection20).
　The third term, intra-group means an ability to sur-
vive among a small number of group members21, 22). 
Groups can include family and/or others. 
　The fourth term, inter-group, means knowledge for 
forming relationships among complex groups, including 
between neighboring groups. This knowledge includes 
that necessary for coexistence, competition, and conflict 
in order to maintain and expand one’s own group’s ter-
ritory and status. It is likely that only humans have ac-
quired this fourth ability.
　Brain functions evolved for each of these four interac-
tion types differentially. The function of the emotional 
system is also different for each sub-system (Fig. 2).
crete emotions in humans or primates. However, the 
number of basic emotions depends on each researcher9). 
Ekman introduced six basic emotions from human fa-
cial expression, while Panpsepp proposed four emotions 
as basic emotions from animal behavior, thus these ap-
proaches have not categorically fixed the number of 
basic emotions.
　It is suggested that emotion theory4) can be generally 
classified into the single-system model10), the dual-sys-
tem model11, 12), and the multiple-system model8). Also 
there are cognitive and social constructionist theories of 
emotions13). Various theories have been developed about 
emotions, but we are far from a unified theory of uni-
versal emotions.
　Recently, neuroscience research has started report-
ing on emotion on the basis of brain mechanisms. The 
brain is one unit, and it is believed that all affects are 
controlled in the brain. Humans experience various af-
fective feelings from primitive emotions of well and un-
well states to higher emotional feelings which are 
thought to be uniquely human such as love and guilt. 
Among these higher emotional feelings, social emotions 
in the real world are mainly found in primates and hu-
mans. Emotions can be studied at many different hier-
archical levels14,15), and at present there is too little 
cross-talk among researchers investigating distinct lev-
els of emotion. In this paper we suggest a hypothesis 
regarding how emotions can be classified as a whole 
which corresponds to brain functions developed through 
evolution.
1. Hierarchical hypothesis of evolutional emotions
　The brain is one whole unit, and it is common sense 
that emotions are controlled by the brain. However, this 
does not mean that it is possible to explain the emotion 
mechanism using one unified theory spanning lower an-
imals to humans. It is reasonable that emotional feelings 
in humans consist of several separate sub-systems 
structurally and functionally as a result of evolution.
　MacLean suggested initially that the brain shows a 
structural evolutional hierarchy15). According to this 
model of brain evolution, the brain is divided conceptu-
ally into three levels, the reptilian brain, the old mam-
malian brain, and the new mammalian brain. The early 
animal lived in the sea using only a small number of 
neurons, and such a small brain could only perform sim-
ple information processing for bodily control and simple 
movements16). Through evolution the brain became 
larger and more complicated, developing into the hu-
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Fig. 1　 Evolutional hierarchical model of emotions/feelings in humans. Human feelings consist 
of four sub-systems of primitive emotions, core emotions, social emotions/feelings and 
intellectual feelings, to higher control of affective behavior. The hypothesis is also 
based on subject relationships with the environment and others, intra-individual, in-
ter-individual, intra-group and inter-group, respectively. Evolution shows expansion of 
subjects to the self and others, progressing according to sensory and motor processing 
abilities. The primitive emotions are well and unwell states, and core emotions are only 
the five basic emotions of pleasure, acceptance/love, fear, disgust and anger for sur-
vival of individual animals in the predator-prey relationship and sexual selection. Social 
emotions/feeling are love, familiarity, hate, etc, that are important in bonding and fight-
ing in group. Intellectual feelings are agape and guilt, for example, and are man-made.
Fig. 2　 The putative brain model for the evolutional hierarchical hypothesis of emotions/feel-
ings in humans. The human brain is divided functionally into four sub-systems of the 
primitive brain, the emotional brain, the social brain and the intellectual brain. The 
primitive brain is mainly related to the midbrain and hypothalamus, the emotional brain 
to the limbic system, the social brain to the paleocortex and cortex, and the intellectu-
al brain to the neocortex, respectively.  External information enters differentially to 
each area. Contrastingly internal information passes through the hypothalamus. Each 
sub-brain corresponds functionally to maintenance of the body, individual and group 
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Core emotions
　With evolution, the requirement for higher energy 
effectiveness of food such as meat protein was import-
ant for animals. Such a relationship between prey and 
predator among fish is easily found in the sea. More 
severe competition emerged after animals crawled out 
of the sea onto the ground. Here animals had to acquire 
various escape behaviors to avoid predation. New abili-
ties to discriminate friend from enemy were required to 
escape dangerous situations and to arrest movement 
and to hide from predators. It is impossible to perform 
these functions with primitive emotions in the primitive 
brain. Thus a new brain area evolved which included a 
new decision-making, or choice function to cope with 
the complexity of the environment. Core emotions, one 
of the new decision-making systems, were evolved 
when mammals climbed onto the ground from the sea, 
and survived in the complex environments. Core emo-
tions might be basically classified into five emotions 
through evolutions of behavioral repertories; pleasure, 
fear, disgust, acceptance and anger (Fig. 1). Pleasure 
and acceptance/love are based on mechanisms of re-
wards, and fear, disgust and anger are based on pain. 
Pleasure, fear and disgust emotions contribute to pro-
tect the body from predatory animals and to protect 
the body from bad food. Identification of friend or ene-
my is also very important to survival. The discrimina-
tion capacity of visual and auditory information was 
dominant, and then the role of odor and somatosensory 
processing capacity changed to auxiliary systems of de-
cision-making due to visual and auditory processing.
　On the other hand, regarding species maintenance, 
sexual competition around males and females became 
strict as animals evolved from agamogenesis to game-
togony.  Intersexual selection became severe because of 
selfish genes20). This led to the new emotions of accep-
tance/love and anger as necessary conditions to sur-
vive sexual competition and raise children. These emo-
tions induced both attack and attach behaviors. As for 
relationships in this stage, predator and spouse are im-
portant, meaning inter-individual relationships hold.
　Thus the repertoire of animal behavior expands and 
shows increasing diversity. The core emotions of plea-
sure, fear, disgust, acceptance/love and anger in this 
way might contribute to select and choose correspond-
ing behaviors, as a minimum requirement. These five 
different kinds of emotions were developed together in 
the larger brain such as the emotional brain. 
　Various researchers list basic emotion theories, but 
Primitive emotions
　The central nervous system evolved from the physi-
cal accommodative needs of multi-cellular organisms. 
For example, the CNS of the ascidian is unique so that 
only the ganglion controlling the internal organs re-
mains after it loses active movement at the larval stage 
and remains fixed at a stationary location16). Its ganglion 
works as an autonomic nervous system regulating in-
ternal control to maintain homeostasis16). A nervous sys-
tem contributing to a motor and sensory system is re-
quired when movement evolves. Also, as a necessity 
condition, the primitive nervous system has to involve 
most important functions for the maintenance of life, 
so-called instinct functions in animals. They include the 
CNS to regulate maintenance of energy and nutritional 
supplies, fluid balance, and body temperature regula-
tion for survival in the environment19).
　Perhaps initial food could be phytoplankton and ani-
mal corpses17). Cerebral functions in a primitive sea 
were enough only for finding simple food so the diges-
tive system was not complicated. These abilities to 
choose food sources were functions dependent on well 
and unwell categorization, which is involved in primi-
tive reward and disgust functions using chemical reac-
tions. These processes do not require complex sensory 
information from the external environment and do not 
require rapid motor function, because there were no 
predatory animals to avoid. In this stage, the main func-
tion of the motor system is reflex of movement and 
control of fixed action patterns. Also taste, smell and 
touch sensations were important in sensory discrimina-
tion at an early stage of evolution.
　What is an emotion at the first stage of evolution? 
Fear is likely not present as an emotion at this initial 
stage. As a sufficient condition of the brain to maintain 
only life support, primitive emotions are defined to be 
well and unwell sensations related to body conditions 
(Fig. 1). At the early phase of evolution, the brain was 
not capable of complex abilities such as the core emo-
tions of the next stage. Classical conditioning was an 
important function for interacting with the environ-
ment at this stage, and motor programs of both ap-
proach and avoidance behavior were transcribed at the 
genetic level. The main brain function at this stage is to 
maintain the body’s internal environment. The neces-
sary conditions to this are only the ability to move to 
suitable environments, including securing energy and 
maintaining water and temperature balance.
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study primate emotions. Human use of symbolic letters 
became possible through the evolution of the cerebral 
cortex. The ability to generalize and use abstract think-
ing was necessary to utilize symbolic writing, and as a 
result, we were able to form cultures26). Cultural differ-
entiation is limited among primates, while humans can 
build complex relationships among groups outside of 
family connections, leading to new feelings which deep-
en social life, characteristics unique to humans. For ex-
ample, agape, the love of God, is a human feeling with-
out a corollary among primates. Also, crime, depen-
dence, and mercy occurred in specific areas in the past 
and have since propagated all over the world. Cultural 
technology propagated and has shaped the modern 
world. It might be possible to classify these complex 
human emotions as social feelings, but social feelings 
have progressed to another stage of evolution in hu-
mans. Traces of these might be found in primates, but 
they developed considerable additional complexity in 
human society. We define intellectual feelings as unique 
human feelings here27).
2. Brain and emotion
　Our hypothesis is that functional emotion consists of 
four sub-systems which are organized in a hierarchy 
based on their order of evolution. However, it is not 
clear whether cerebral structure supports the hierar-
chical characteristics of this emotion theory. Evolution 
suggests the brain developed to be more complex and 
bigger over time. MacLean’s triune brain model has a 
well-known cerebral hierarchy15). According to brain 
evolution, the brain is divided conceptually into three 
sub-structures of the reptilian brain, the old mammalian 
brain, and the new mammalian brain. The most ancient 
structure is the reptilian brain and includes the basal 
ganglia, or extrapyramidal motor system15). This area 
controls autonomic primitive behavioral responses in-
cluding whole-body movements related to instinctual 
behaviors. The next level in MacLean’s model is the old 
mammalian brain, composed of limbic system, which 
controls basic emotions related to social relationships. 
These two levels are similarly organized in all mam-
mals. The third level is the neocortex, which is the big-
gest among humans. 
　Panksepp also proposed three sub-systems, the in-
stinctual motor brain, the emotional brain and the ratio-
nal brain8).　He introduced four basic behaviors of seek-
ing, fear, panic, and rage, related to a basic emotion 
theory. The instinctual motor brain controls metabolic 
no fixed emotion theory exists9).  The famous basic emo-
tion theory of Ekman was derived through examination 
of human expression, and then could not fit animal be-
havior6). 
Social emotions/feelings
　Animals formed groups as part of their evolution. 
The main merits of forming groups are protection from 
predatory animals and larger animals which are stron-
ger, and to hunt through cooperation. Contrastingly 
groups also have the demerits of food sharing. Howev-
er, the merits outweighed the demerits, making groups 
more successful. Groups were initially formed through 
blood relationships. If a hierarchical rank is formed of a 
larger group, the probability to get food and a spouse is 
equivalent to advancing to the higher ranks in the soci-
ety.
　Recently social intelligence, defined as the ability to 
maintain relationships among individuals, has been 
shown to be important through the outdoor observation 
of chimpanzees21, 22) through things such as empathy, 
alliance, deceit, etc. The advantage social intelligence 
offers is that individuals can remain members of groups 
through using these abilities. Further behavioral vari-
ety in the form of feeling and emotions are required to 
be social such as sorrow, shyness, love, shame, etc. For 
example, empathy to one’s partner’s sorrow, adds to 
intimacy and increases opportunities to generate off-
spring, perpetuating individual genes23, 24). Outdoor ob-
servation also shows some monkeys require alliances or 
cooperation with other males to get or maintain the 
dominant male position in the group25). As the group 
population increases, third person relationships increase 
rapidly. An individual cannot keep their position in a 
group without understanding such relationships, and it 
is difficult to maintain relationships in the group through 
only core emotions. Animals cannot form a group only 
in anger, and so the ability to inhibit anger is required. 
These are so-called social emotions/feelings. The word 
feelings is used because the formation of self-conscious-
ness is found in chimpanzees, and also the origin of hu-
man feelings is pointed toward through chimpanzee’s 
expression of such feelings.
Intellectual feelings
　The final aim of studying feelings is to understand 
human feelings. The origin of feelings in humans can be 
inferred from primates, but such inferences do not lead 
to complete understanding of human feelings even if we 
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self-contained feeding and drinking behaviors29). The en-
docrine system for maintenance of the internal environ-
ment is controlled through a pituitary gland, and the 
nucleus of the autonomic nervous system is also pres-
ent in the hypothalamus. Minimum survival is possible 
without the brain higher than the hypothalamus. On 
the contrary, the fear reaction does not appear even if 
we stimulate the hypothalamus. Olds discovered an in-
tracranial self-stimulation, where the animal wants to 
stimulate a certain brain area, and proposed a reward 
system30). He also proposed the punishment system30). 
The hypothalamus thus controls primitive positive and 
negative reinforcements through instinct behavior and 
autonomic control.
　Electrophysiological study showed that the lateral 
hypothalamus neurons in monkeys responded to inges-
tion of food31~33) and water34). This response to food cor-
responds with satiation from food intake32, 33).
　Recently it has been shown that the dopamine sys-
tem in the mesencephalon tegmentum nuclei of the 
midbrain contributes to a reward system35). Also, the 
classical neurotransmitter serotonin and noradrenaline 
originate in the mesencephalon. These transient long 
fibers mean primitive emotions and primitive motiva-
tions are influenced by higher sub-systems in the brain.
Emotional brain
　The part of the brain that corresponds to the core 
emotions is the limbic system, which is equivalent to 
MacLean’s old mammalian brain15). The amygdale has 
been identified as a site to control fear36, 37). Systematic 
anatomical analysis indicates that the central nucleus of 
the amygdale has a role in the output of emotional ex-
pressions. Its fear information is sent to the hypothala-
mus to regulate internal control of the body. The hypo-
thalamus and brainstem are thought to be the output 
region for internal reflexes involved in freezing behav-
ior38). A lesion study showed that the amygdale controls 
recognition and memory in fear36). In fact, amygdalar 
neurons responded to the sight of objects related to 
fear such as syringes and gloves catching, etc39~41). In 
primates, amygdalar neuron response is more respon-
sive to visual information of objects than the lateral hy-
pothalamic neurons42).
　The amygdala receives taste information from the 
gustatory cortex and neurons responded to the taste of 
preferred juice or non-preferred saline39). Also the 
amygdala and insula cortex are related to taste aver-
sion conditioning43). The medial part of the amygdale is 
and hormonal balance through the lateral hypothala-
mus, and seeking circuits including the ventral basal 
ganglia and the brainstem. The emotional brain corre-
sponds to the limbic system and controls fear, panic and 
rage.  The rational brain is especially unique in humans. 
Thus the brain has a hierarchical system. Higher func-
tions can operate only on the basis of lower functions, 
but lower functions can operate independently of high-
er ones.
　Rolls also proposed a different hierarchical diagram 
that pointed out behavioral information processing from 
sensory processing to motor control12). The first tier cor-
responds to sensory processing of visual, taste, olfaction 
and somatosensory information in the cortex. This level 
contributes processing of ‘what’ information from the 
external environment. The next tier is a level of evalu-
ation of reward and affect in the central nervous sys-
tem. He proposed these areas to be the lateral PFC, the 
amygdala and the orbitofrontal cortex. Of these, the 
orbitofrontal cortex is a central site of evaluation and 
reinforcement of motivational behavior. The third tier is 
a level of decision-making and output control, which 
corresponds to the medial PFC, the cingulate cortex, 
the striatum, and the lateral hypothalamus. The lateral 
hypothalamus is related to control of autonomic and en-
docrine output responses, and also ingesting energy 
and water balance behavior. This model of three tiers is 
mainly introduced through the neuro-computer model 
of motivational and emotional behaviors12). 
　On the other hand, our evolutional model of emotions 
is focused on functional discrimination of complex emo-
tional representations and their corresponding brain 
areas (Fig. 2).
Primitive brain
　A minimum condition to define the primitive brain is 
that animals have acquired an ability to survive and 
maintain their bodies autonomously. This means that 
the brainstem might be excluded, because an animal 
isolated to only a brainstem does not survive. Thus, 
primitive emotions are related to both the midbrain and 
the hypothalamus, and also include a ventral part of the 
basal ganglia as motor output28). These regions are old 
evolutionarily, and the hypothalamus controls instinct 
behavior for animals to live in the environment. It also 
includes behaviors to regulate maintenance of energy 
and nutritional supplies, fluid balance and body tem-
perature regulation, for survival in the environment19). 
Stimulation of the lateral hypothalamus can induce 
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identified to be linked to regions in the tempo-parietal 
junction and prefrontal cortices53, 54). The tempo-parietal 
junction supports the uniquely human ability to reason 
about the contents of mental states. The medial pre-
frontal cortices are implicated in emotional empathy 
and human representation of triadic relations between 
two minds and an object. In future, these themes will be 
main targets for research.  Recently, high quality data-
bases of fMRIs of humans are being assembled. These 
studies will contribute evidence to indicate a difference 
between humans and primates45). Human uniqueness 
can only be applied to humans and the definition of 
human uniqueness is obvious, since humans construct 
history, culture, science and technology.
　In the hierarchical model described here, higher func-
tions are relatively open, while lower levels are closed. 
Animals with higher brains can control flexible behav-
ior in complex external situations.　 Within the intellec-
tual brain, the human brain displays many unique orga-
nizational functions such as speaking, thinking and 
planning.
Conclusions
　We proposed four sub-systems of emotions/feelings 
from a theory of evolution classification of lower ani-
mals to humans. They are primitive emotions, core 
emotions, social emotions/feelings and intellectual feel-
ings, respectively. It is useful for discussing emotions to 
distinguish the qualitative differences between these 
hierarchies. Particularly, identification of intellectual 
feeling in humans does not lead to confusion with the 
animal emotions, and suggests clear differentiation be-
tween humans and animals. We argued about the brain 
structure correspondence for these four sub-systems of 
emotions/feelings. The human brain basically has a 
structural and functional hierarchy, though some over-
lap was seen functionally. Future brain image studies 
will contribute to identification of the intellectual feel-
ings characteristic of humans.
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the first-line treatment for advanced PCa to suppress 
androgen action. Most patients respond to this treat-
ment initially; however, the PCa eventually becomes 
castration-resistant, and is then often subsequently le-
thal. Nevertheless, even in this castration-resistant 
state, androgen and the androgen receptor (AR) remain 
Introduction
　Prostate cancer (PCa) is one of the leading causes of 
death from cancer in males in Western countries and is 
the sixth most common cause of cancer mortality in 
Japanese males.1) PCa is initially androgen dependent, 
and castration (androgen deprivation therapy, ADT) is 
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・Radiological progression: The appearance of two 
or more bone lesions on bone scan or enlargement of 
a soft tissue lesion using RECIST. 
　Observation of the response after anti-androgen with-
drawal or second- and third-line hormone therapies is 
important.9,10) However, no associated survival benefit 
has ever been reported for such treatments. In addition, 
the description of anti-androgen withdrawal is not in-
cluded in the latest CRPC definition from the EAU. A 
similar definition of PCa progression is included in the 
Prostate Cancer Working Group 2.11)
　In the General Rules for Clinical and Pathological 
Studies on Prostate Cancer (Japan), CRPC is defined as 
being present when clinical and/or PSA progression is 
found even if the serum testosterone level is maintained 
below 50 ng/dL either by surgical or medical castration, 
regardless of the use of anti-androgens.12) Therefore, it 
is necessary to keep in mind that the CRPC definition 
varies among studies, and may be changed in the fu-
ture.
II. The mechanisms underlying the development and 
progression of castration-resistant prostate cancer
　Scher et al. classified PCa based on its androgen-de-
pendency and hormone sensitivity according to the tu-
mor response to treatments under various situations.13) 
In this scheme, a tumor that is proliferating despite cas-
trate levels of testosterone, and that responds to addi-
tional hormonal manipulation is considered to be andro-
gen-independent but hormone-sensitive. A tumor that 
has not responded to sequential hormonal manipula-
tions is androgen-independent and hormone-insensitive. 
It is the latter tumors that are typically classified as 
hormone refractory. When a tumor can be called andro-
gen independent and hormone sensitive, a decrease in 
proliferation may be observed in response to adrenal 
androgen blockade, corticosteroids, anti-androgen with-
drawal or other hormonal manipulations.
　The potential mechanisms of the castration-resistant 
progression of PCa are summarized in Table 1.14,15) The 
key issue is that androgen and the androgen receptor 
are involved in most cases of CRPC; AR amplification is 
found in about 30% of cases and hyperactivated AR 
mutations are present in 20-40% of the patients with 
progression of PCa.16)
A. AR hypersensitivity
　Masai et al. reported that the percentage of strongly 
positive cancer cells of the prostate was inversely cor-
active in the progression of PCa. Therefore, the terms, 
“hormone-refractory prostate cancer” or “androgen-in-
dependent prostate cancer” are now thought to be inap-
propriate; castration-resistant prostate cancer (CRPC) is 
now being widely used instead, because more effective 
androgen suppression or AR-targeted therapies can 
still be used to treat such patients.2) The definition of 
CRPC, the mechanisms underlying its development and 
progression and the progress in the treatment of CRPC 
are reviewed in this article.
I. The definition of castration-resistant prostate cancer
　The precise definition of recurrent or relapsed PCa 
remains controversial. Several groups have published 
practical recommendations for defining CRPC. Howev-
er, the definition of castration-resistant progression has 
varied among studies3～5). In the guidelines on PCa 2012 
(also 2013) from the European Association of Urology 
(EAU), the definition is described as follows6) :
・Castrate serum levels of testosterone (testosterone 
< 50 ng/dL or < 1.7 nmol/L).
・Three consecutive rises of prostate specific antigen 
(PSA), 1 week apart, resulting in two 50% increases 
over the nadir, with a PSA > 2 ng/mL.
・Anti-androgen withdrawal for at least 4 weeks for 
flutamide and for at least 6 weeks for bicalutamide*
・PSA progression, despite consecutive hormonal 
manipulations†
* Either anti-androgen withdrawal or one secondary 
hormonal manipulation should have been done in 
order to fulfill the criteria for CRPC if patients have 
been treated with anti-androgens in the context of 
maximum androgen blockade or step up therapy fol-
lowing PSA progression after failure of luteinizing 
hormone-releasing hormone (LHRH) treatment.
†Progression of osseous lesions: progression or ap-
pearance of two or more lesions on bone scan or soft 
tissue lesions using RECIST (Response Evaluation 
Criteria in Solid Tumours), and with nodes > 2 cm in 
diameter.7)
These criteria indicate that PSA progression was the 
main condition required to define progression. In 2014, 
this definition was changed as follows8):
・Castrate serum testosterone < 50 ng/ml or 1.7 
nmol/L plus either: Biochemical progression: Three 
consecutive rises of PSA, 1 week apart, resulting in 
two 50% increases over the nadir, with PSA > 2 ng/
mL.
or
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gen concentration.
B. Intra-tumoral androgen synthesis
　When castration therapy is administered, either sur-
gically or with a LHRH agonist, it has been demonstrat-
ed that dihydrotestosterone (DHT) can still be detected 
in locally recurrent and metastatic prostate cancer tis-
sue at levels that are sufficient to activate the AR. The 
two dominant sources of androgens in males with CRPC 
are the adrenal androgens, dehydroepiandrosterone 
(DHEA) and DHEA-sulfate (DHEA-S), and de novo syn-
thesis by the prostate gland.22,23) Nishiyama et al. demon-
strated that the DHT levels in prostate tissue after 
ADT remained at approximately 25% of the amount 
measured before ADT. The DHT levels in serum de-
creased to approximately 7.5% after ADT. The level of 
DHT in prostatic tissue before ADT was not correlated 
with the serum level of testosterone. The serum levels 
of adrenal androgens were reduced to approximately 
60% after ADT. The source of DHT in prostatic tissue 
after ADT is thought to involve intracrine production 
within the prostate, wherein adrenal androgens are 
converted to DHT. Targeting the DHT still remaining 
in prostate tissue after ADT may require new thera-
pies to reduce intratumoral androgen synthesis.24) 
　Montgomery et al. reported that castration-resistant 
metastases displayed alterations in genes encoding ste-
roidogenic enzymes, including upregulated expression 
of FASN, CYP17A1, HSD3B1, HSD17B3, CYP19A1, and 
UGT2B17, and downregulated expression of SRD5A2 
(P<0.001 for all), compared with the levels in primary 
prostate tumors. Metastatic PCas from anorchid males 
were found to express transcripts encoding andro-
related with the grade. Relapsed cells showed a low 
population of strongly positive cells, irrespective of the 
grade. These findings mean that the AR still exists 
even in cells treated by androgen deprivation.17) In later 
studies, Visakorpi’s group reported AR amplification in 
hormone refractory PCa cells. Comparative genomic 
hybridization studies showed that amplification of the 
Xq11-q13 region (the location that encodes the AR), is 
common in tumors recurring during ADT. They found 
high-level AR amplification in seven of 23 (30%) recur-
rent tumors, but in none of the specimens taken from 
the same patients prior to therapy.18) Hormone-refracto-
ry tumors expressed the AR and showed, on average, 
six-fold higher expression than androgen-dependent tu-
mors or benign prostate hyperplasias (P<0.001). Four of 
13 (31%) hormone-refractory tumors contained AR gene 
amplification detected by fluorescence in situ hybrid-
ization. Androgen-independent tumors with gene ampli-
fication expressed, on average, a two-fold higher level of 
the AR than did the refractory tumors without the 
gene amplification.19) AR amplification can also be de-
tected in circulating tumor cells.20)
　Using microarray-based profiling of isogenic PCa xe-
nograft models, Chen et al. found that a modest increase 
in AR mRNA was the only change consistently associ-
ated with the development of resistance to anti-andro-
gen therapy. This increase in AR mRNA and protein 
expression was both necessary and sufficient to convert 
PCa growth from a hormone-sensitive to a hormone-re-
fractory stage, and was dependent on a functional li-
gand-binding domain.21) These findings indicated that 
AR amplification emerges during ADT by facilitating 
tumor cell growth in an environment with a low andro-
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b. Intra-tumoral androgen
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+ + Production of androgen within tumor cells
c. Change of AR specificity due to
mutations
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alternative signaling pathways (STAT3, MAPK, Akt, cSrc); 
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signaling pathways; methylation of the AR promoter
f. Proliferation of pre-existing
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- - Malignant epithelial stem cells
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AR gene of LNCaP cell line contains one mutation at 
codon 877 (Thr to Ala). The growth of LNCaP cells is 
stimulated in vitro by a wide variety of substances, in-
cluding androgens, estrogens, progesterone and several 
anti-androgens, indicating the broadened ligand respon-
siveness of AR mutants.29) 
　Sack et al. analyzed the crystallographic structures of 
the AR ligand-binding domain (LBD). The AR LBD is 
monomeric, possibly because of the extended C termi-
nus of the AR, which lies in a groove at the dimerization 
interface. The binding of the natural ligand, DHT, by 
the mutant LBD involves interactions with the same 
residues as in the wild-type receptor, with the excep-
tion of the side chain of threonine 877, which is an ala-
nine residue in the mutant. This structural difference in 
the binding pocket may explain the ability of the mu-
tant AR found in LNCaP cells (T877A) to accommodate 
progesterone and other ligands that the wild-type re-
ceptor cannot.30) The same mutation was the most fre-
quently found in clinical practice, especially within the 
patients who underwent maximal androgen blockade 
using flutamide.31) 
　Given that certain mutations can alter AR ligand 
specificity, AR mutations might play a key role in ‘an-
ti-androgen withdrawal syndrome’.32,33) This phenome-
non occurs in a subset of patients with castration-resis-
tant progression. The cessation of anti-androgen medi-
cation improves the symptoms and the serum PSA 
levels decrease, suggesting that the anti-androgen acts 
agonistically in the tumor cells to promote growth. Our 
previous study found that in two of four patients who 
experienced improvement after anti-androgen with-
drawal, AR mutations had occurred during anti-andro-
gen treatment.#32) These mutations were identical to 
that in LNCaP cells (T877A), and were not detected in 
untreated tumors. Furthermore, it is known that AR 
mutations such as Trp741Cys or Trp741Leu are acti-
vated by bicalutamide.#34)
D. Ligand-independent AR activation
　Androgen-independent activation of the AR mediates 
the castration-resistant progression of PCa in the ab-
sence of androgen. By using intracellular signaling 
pathways involving epidermal growth factor (EGF), in-
sulin-like growth factor-I (IGF-I), keratinocyte growth 
factor (KGF), interleukin-6 (IL-6) or HER2/neu, phos-
phorylation occurs in tyrosine residues or serine and 
threonine residues of the AR, and the AR is then acti-
vated without androgens.14,35～37) Several clinical investi-
gen-synthesizing enzymes and to maintain intratumoral 
androgens at concentrations capable of activating AR 
target genes and maintaining tumor cell survival.25) Dil-
lard et al. reported that established androgen-indepen-
dent PCa cell lines, PC3 and DU145, expressed the 
mRNA and proteins for scavenger receptor type B1 
(SRB1), steroidogenic acute regulatory (StAR) protein, 
cytochrome P450 cholesterol side chain cleavage 
(P450scc), 3beta-hydroxysteroid dehydrogenase (3be-
ta-HSD) and other enzymes involved in androgen bio-
synthesis. Moreover, the expression of all these proteins 
and enzymes was significantly higher in the andro-
gen-independent derivative of LNCaP PCa cells (C81) 
than in the androgen-dependent parental cell line (C33). 
　In serum-free cultures, the androgen-independent 
C81 cells secreted approximately five-fold more testos-
terone than C33 cells, as determined by immunoassays 
of the conditioned media. These cells could also directly 
convert radioactive cholesterol into testosterone, which 
was identified by thin layer chromatography. These re-
sults show that PCa cells in advanced stages of the dis-
ease could synthesize androgens from cholesterol, and 
hence, are not dependent upon testicular and/or adre-
nal androgens.26) In addition, Bertaglia et al. reported 
that serum testosterone levels lower than the currently 
adopted cutoff of 50 ng/dL have a prognostic role in 
patients with PCa receiving LHRH agonists, and are a 
promising surrogate parameter of LHRH agonist effica-
cy. Using a receiver operating characteristic curve, it 
was found that a testosterone value of 30 ng/dL offered 
the best overall sensitivity and specificity for the pre-
diction of death, with serum testosterone levels <30 ng/
mL associated with a significantly lower risk of death 
(adjusted HR, 0.45; P =0.034).27) It has been suggested 
that the maximal therapeutic efficacy in the treatment 
of CRPC will require agents capable of lowering the 
androgen level as much as possible, as well as inhibiting 
the intracrine steroidogenic pathways within the pros-
tate tumor microenvironment.25)
C. Mutations in the AR gene
　Mutations in the AR gene have been detected in 
about 10–20% of PCa specimens. The frequency of mu-
tations is generally higher in hormone-refractory, meta-
static tumors compared with untreated, lower-grade 
primary tumors.16) The initial drive to deal with AR 
gene mutations in PCa originated from a study of the 
LNCaP cell line, which was derived from a metastatic 
lesion of the lymph nodes of a patient with PCa.28) The 
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bodies specific to AR-V7 frequently detected the AR-V7 
protein in HRPC specimens, but rarely in hormone-näive 
PCa specimens. AR-V7 was localized in the nuclei of 
cultured PCa cells under androgen-depleted conditions, 
and was constitutively active, thus driving the expres-
sion of canonical androgen-responsive genes, as re-
vealed by both AR reporter assays and expression mi-
croarray analysis.44) In addition, CRPC positive for AR-
V7 did not respond to abiraterone or enzalutamide, and 
the patients showed significantly shorter survival.45) 
Therefore, AR variants may be explored as potential 
biomarkers and therapeutic targets for advanced PCa.
E. Bypassing the AR
1. Neuroendocrine differentiation (NED)
Neuroendocrine (NE) cells exist within prostatic ducts 
and acinar cells. These cells regulate the differentiation, 
proliferation and secretion of the prostate. The AR is 
not expressed in NE cells, and NED is thought to under-
lie one of the mechanisms by which cells undergo cas-
tration-resistant progression, because of its androgen-in-
dependence. In the majority of PCa cases, malignant NE 
cells were also found in tumor tissues to some extent. 
There is no clear definition of NED; however, a region 
is defined as having undergone NED if NE markers are 
positive by immunohistochemical staining. This is a ba-
sic feature of the prostate, regardless of whether it is 
benign or malignant. NE cells express certain peptide 
hormones or pro-hormones, which affect the target cells 
by endocrine, paracrine, autocrine and/or neuroendo-
crine transmission in an androgen-independent fash-
ion.46) Neuroendocrine markers can be measured in se-
rum or plasma samples. Chromogranin A, neuron-spe-
cific enolase and ProGRP have prognostic significance 
in PCa. Among these, serum chromogranin A is thought 
to be the most important, and the pretreatment serum 
levels of chromogranin A are associated with castra-
tion-resistant progression. 
　NED can be a therapeutic target.47) During endocrine 
therapy in metastatic PCa patients, the serum chro-
mogranin A values were not related to the serum PSA 
levels, and increased as the treatment periods increased. 
It has been suggested that the chromogranin A velocity 
has the potential to predict androgen-independent pro-
gression after endocrine therapy.48) In addition, we have 
reported that strong NED found in a prostate biopsy 
specimen at the time of castration-resistant progression 
correlates with significantly poorer survival.49) 
　The mechanisms underlying how NED induces cas-
gations have shown that the serum levels of the IL-6 
are significantly elevated in patients with castration-re-
sistant disease.38,39) These findings indicate that IL-6 is 
involved in the androgen-independent progression of 
PCa. 
　Ueda et al. demonstrated a mechanism of cross-talk 
between the IL-6 and AR signal transduction pathways 
in LNCaP human PCa cells. IL-6 induced several andro-
gen response element-driven reporters that were de-
pendent upon the AR, that increased the phosphoryla-
tion of mitogen-activated protein kinase (MAPK) and 
activated the AR N-terminal domain (NTD). Inhibitors 
of MAPK and JAK decreased the IL-6-induced phos-
phorylation of MAPK and activation of the AR N-termi-
nal domain (NTD). Immunoprecipitation and transacti-
vation studies showed a direct interaction between 
amino acids 234-558 of the AR NTD and STAT3 follow-
ing IL-6 treatment of LNCaP cells. The activation of the 
human AR NTD by IL-6 was mediated through MAPK 
and STAT3 signal transduction pathways in LNCaP 
PCa cells.37) 
　In clinical practice, significant suppression of serum 
IL-6, through inhibition of androgen-independent activa-
tion of the AR, is thought to be one of the mechanisms 
underlying the effects of dexamethasone therapy in 
PCa patients with progressive disease. The change in 
serum IL-6 levels was significantly associated with the 
response to dexamethasone in the treatment of 
CRPC.40～42)
　Recently, altered AR splicing patterns have been 
identified as a mechanism of PCa progression and resis-
tance to ADT. Several studies have described the syn-
thesis of alternatively spliced transcripts encoding trun-
cated AR isoforms that lack the ligand-binding domain, 
which is the ultimate target of androgen depletion. 
Many of these truncated AR isoforms function as con-
stitutively active, ligand-independent transcription fac-
tors that can support androgen-independent expression 
of AR target genes, as well as the androgen-indepen-
dent growth of PCa cells.43) Luo’s group reported seven 
AR variant transcripts lacking the reading frames for 
the ligand-binding domain due to the splicing of “intron-
ic” cryptic exons to the upstream exons encoding the 
AR DNA binding domain. AR-V1 and AR-V7 mRNA 
showed an average 20-fold higher expression in CRPC 
(n=25) when compared with hormone-näive PCa (n=82; 
P<0.0001). Among the hormone-näive PCa cases, higher 
expression of AR-V7 predicted biochemical recurrence 
following surgical treatment (P=0.012). Polyclonal anti-
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the HGF/c-Met pathway may be of benefit when com-
bined with current androgen ablation treatment.53) 
　Yasuda et al. reported that HGF-related serum mark-
ers could be prognostic markers. The serum active 
HGF (AHGF) levels were increased in patients with 
stage D or D3 compared with stage B disease. In addi-
tion, there were significant differences in the serum 
AHGF levels between patients with well-differentiated 
and poorly-differentiated adenocarcinoma. Further-
more, the mean serum AHGF/THGF ratio in patients 
with stage D3 PCa was significantly higher than that in 
patients with stage B PCa.54) Hepatocyte growth factor 
activator inhibitor type-1 (HAI-1) inhibits hepatocyte 
growth factor activator and matriptase. The expression 
of HAI-1 detected by IHC in patients with PCa was 
significantly higher than that in the patients with a neg-
ative prostate biopsy. CRPC tumors exhibited signifi-
cantly lower HAI-1 expression than untreated metastat-
ic PCa. The PSA progression-free rate was worse in 
patients without HAI-1 expression than in those with 
positive HAI-1 expression.55)
3. The inhibition of apoptosis
Apoptosis, which is usually induced by ADT in PCa, is 
suppressed by the inactivation of tumor suppressor 
genes, or the activation of oncogenes and anti-apoptotic 
genes. Mutations in TP53 and PTEN are found in a 
subset of CRPC.56,57) Bcl-2 causes an anti-apoptotic effect 
by inhibiting the activation of caspase required for the 
induction of apoptosis. Furuya et al. reported the fre-
quency of bcl-2 protein expression using immunocyto-
chemical staining during the progression of human PCa 
from an androgen-sensitive non-metastatic phenotype 
to an androgen-independent metastatic phenotype. Five 
(17%) of the 30 lymph node metastases from pathologi-
cally disseminated D1 disease and 14 (52%) of 27 bone 
metastases from pathologically disseminated D2 disease 
expressed detectable bcl-2 protein. These data demon-
strate that there is a statistically significant (P<0.05) 
association between the expression of bcl-2 and the pro-
gression of human prostatic cancer cells to a metastatic 
phenotype.58) 
　Similarly, McDonnell et al., immunohistochemically 
evaluated androgen-dependent and androgen-indepen-
dent prostate carcinomas for bcl-2 expression. Bcl-2 was 
undetectable in 13 of 19 cases of androgen-dependent 
cancers. In contrast, androgen-independent cancers dis-
played diffuse, high levels of bcl-2 staining (P<0.01). 
These findings indicate that bcl-2 expression is aug-
tration-resistant progression in PCa are being investi-
gated. Wu and Huang showed that both the phosphati-
dylinositol 3-kinase-AKT-mammalian target of rapamy-
cin pathway and ERK are activated, but only the for-
mer is required for the NED of cells. Constitutively ac-
tive AKT promoted NED, and a dominant negative 
AKT inhibited it. The activation of AKT by IGF-1 led 
to NED, and the NED induced by epinephrine required 
AKT activation. The authors of that study also showed 
that the AKT pathway is likely responsible for the 
NED of DU145 cells.50) 
　Neuroendocrine-derived parathyroid hormone-relat-
ed protein (PTHrP)-mediated signaling through the epi-
dermal growth factor receptor (EGFR) and Src path-
ways contributes to the phenotype of advanced PCa by 
reducing the AR protein turnover. PTHrP-induced ac-
cumulation of the AR depended on the activity of Src 
and EGFR and subsequent phosphorylation of the AR 
on Tyr (534). PTHrP-induced tyrosine phosphorylation 
of the AR resulted in reduced AR ubiquitination and 
interaction with the ubiquitin ligase COOH terminus of 
Hsp70-interacting protein. These events resulted in in-
creased accumulation of the AR, and thus enhanced the 
growth of PCa cells at low levels of androgen.51)
2. The HGF/cMET pathway
Hepatocyte growth factor (HGF) is a ligand of c-MET. 
This ligand-receptor system promotes proliferation, mi-
gration, invasion, metastasis and anti-apoptosis effects 
in cancer cells, including PCa. HGF is expressed in stro-
mal cells, and its receptor, c-MET, is expressed in an-
drogen-independent PCa cells (PC-3 and DU145), but 
not in androgen-dependent PCa cells (LNCaP).51) There 
is a potential link between androgen signaling and 
c-Met expression in PCa cells. For example, it is known 
that the AR represses the expression of c-Met in a li-
gand-dependent manner. The AR controls HGF/c-MET 
and ADT upregulates this system. Sp1 induces the 
transcription of c-Met, and the AR can repress the 
Sp1-induced transcription in PCa cells. The AR inter-
feres with the interaction between Sp1 and the func-
tional Sp1 binding site within the c-Met promoter. The 
repressive role of androgen signaling on c-Met expres-
sion was confirmed in PCa xenografts. Although the 
currently used androgen ablation therapies can repress 
the expression of growth-promoting genes that are ac-
tivated by the AR, it may also attenuate the repressive 
role of AR on c-Met expression. Therefore, the introduc-
tion of therapeutic strategies to inhibit the activation of 
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would rarely expect to encounter this kind of PCa in 
clinical practice.
III. Treatment of CRPC
The agents for CRPC/HRPC approved by the U.S. Food 
and Drug Administration are summarized in Tables 2 
and 3. The endpoints are largely classified as quality of 
life or palliation and survival.
A. Agents to improve the QOL
　Tannock et al. reported the results of thirty-seven 
patients with symptomatic bone metastases from pros-
tate cancer that had progressed following earlier treat-
ment with estrogens and/or orchidectomy, who were 
treated with low-dose prednisone (7.5 to 10 mg daily).65) 
Thirty-eight percent of these patients showed improve-
ment in indices used to assess pain at one month after 
starting prednisone. The major findings of that study 
were that: (1) low-dose prednisone may lead to pain re-
lief in some patients with advanced PCa. (2) The pain 
relief was associated with suppression of adrenal andro-
gens. (3) Measures of pain and quality of life can be used 
to assess the possible benefits of systemic therapy in 
patients with metastatic PCa.
　Tannock et al. also reported the results of a study 
comparing chemotherapy with mitoxantrone plus pred-
nisone or prednisone alone for symptomatic hormone-re-
sistant PCa in a Canadian randomized trial with pallia-
mented following androgen ablation, and is correlated 
with the progression of PCa from androgen dependence 
to androgen independence.59) Bcl-2 has previously been 
addressed as a therapeutic target in hormone-refracto-
ry PCa, and antisense therapy was also developed for 
the MDM2 oncogene, which regulates p53 and various 
other molecules associated with cancer.60～62) In addition, 
the effects of Bcl-xL of the Bcl-2 family with regard to 
suppressing apoptosis are very strong. Enforced ex-
pression of the Bcl-xL gene dramatically increased the 
cell proliferation in vitro and promoted xenograft tumor 
growth in vivo. Bcl-xL overexpression significantly in-
creased the expression of cyclin D2, which might be 
responsible for Bcl-xL-induced cell proliferation and tu-
mor growth. Therefore, androgen controls Bcl-xL ex-
pression via the AR, and the increased Bcl-xL expres-
sion plays a versatile role in the castration-resistant 
progression of PCa.63)
F. Proliferation of pre-existing androgen-independent 
tumor cells
　Coffey and Isaacs at Johns Hopkins University postu-
lated that the androgen independence of PCa was due 
to a selective growth advantage of preexisting hor-
mone-independent clonal populations of preexisting, 
hormone-independent stem cells. This mechanism is 
likely to be completely independent of androgen- and 
AR-dependent growth stimulation.64,65) However, one 





Indicated for the palliative treatment of patients with metastatic and/or progressive 




1996 QOL Pain related to advanced hormone-refractory prostate cancer
Strontium 89 
chloride
1993 QOL Palliation of painful bone metastases
Samarium 153 1997 QOL Relief of osteoblastic bone pain in cancer patients.
Phosphorus 32 QOL Seldom used -- 89Sr and 153Sm are considered safer agents.
Zoledronic acid 2003 QOL/SRE
The treatment of hypercalcemia of malignancy.
The treatment of patients with documented bone metastases from solid tumors, in 
conjunction with standard antineoplastic therapy. Prostate cancer should have pro-
gressed after treatment with at least one hormonal therapy.
Denosumab 2010 QOL/SRE
The prevention of skeletal-related events (SREs) in patients with bone metastases 
from solid tumors
Denosumab 2011 QOL/SRE
A treatment to increase bone mass in patients who are at high risk of fractures from 
receiving androgen deprivation therapy (ADT) for nonmetastatic prostate cancer 
CRPC, castration-resistant prostate cancer; HRPC, hormone-refractory prostate cancer; QOL, quality of life; SRE, 
skeletal-related event
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dence of a therapeutic response to strontium-89 com-
pared with only a limited placebo effect (P<0.01).
　Zoledronic acid and denosumab are agents that can 
suppress osteoblast and skeleton-related events (SREs), 
defined as pathological fractures, spinal cord compres-
sion, bone pain requiring palliative radiotherapy and 
orthopedic surgery. SREs deteriorate the patients’ qual-
ity of life. Saad et al. studied the effects of a new bis-
phosphonate, zoledronic acid, which blocks bone de-
struction, on the skeletal complications in PCa patients 
with bone metastases.68) In that study, a greater propor-
tion of patients who received placebo had SREs than 
those who received zoledronic acid at a dose of 4 mg 
(44.2% versus 33.2%; P=0.021). The median time to first 
SRE was 321 days for patients who received placebo, 
and was not reached for patients who received zole-
dronic acid (P=0.011 versus placebo). The pain and anal-
gesic scores increased more in patients who received 
placebo than in patients who received zoledronic acid, 
but there were no significant differences in disease pro-
gression. The infusion of 4 mg of Zoledronic acid every 
three weeks reduced SREs in PCa patients with bone 
metastases.
　Fizazi et al. conducted a randomized, double-blind 
study to compare denosumab and zoledronic acid for 
the treatment of bone metastases in males with CRPC.68) 
Denosumab is a human monoclonal antibody against 
RANKL; it also inhibits osteoclast-mediated bone de-
struction. The median time to first on-study SRE was 
20.7 months with denosumab, compared with 17.1 
tive endpoints.66) Palliative responses were observed in 
23 of 80 patients (29%) who received mitoxantrone plus 
prednisone, and in 10 of 81 patients (12%) who received 
prednisone alone (P=0.01). The duration of palliation 
was longer in patients who received chemotherapy (me-
dian, 43 and 18 weeks; P<0.0001, log-rank). There were 
no significant differences in the PSA response or overall 
survival between the groups. Most responding patients 
had an improvement in quality-of-life scales and a de-
crease in the serum PSA level. Based on these studies, 
mitoxantrone plus prednisone and prednisone alone 
were still used as controls in recent randomized con-
trolled trials for the treatment of CRPC. However, mi-
toxantrone is not approved for the treatment of PCa in 
Japan.
B. Bone-targeted therapies
　Strontium-89 chloride, Samarium-153 and Phospho-
rus-32 are radioactive agents used to relieve painful 
bone metastases. Strontium-89 acts as calcium mimic 
and is absorbed by the bone metastases. Lewington et 
al. conducted a prospective, randomized, double-blind 
crossover study to examine the efficacy of strontium-89 
in pain palliation in patients with advanced prostate 
cancer metastatic to bone.67) Dramatic improvement, 
some improvement, no improvement/deterioration 
were found in four, four and four patients in the stron-
tium-89 injection group and zero, three and eleven pa-
tients in the placebo group. A statistical comparison 
between placebo and strontium-89 showed clear evi-
Table 3. Agents with a survival benefit in CRPC/HRPC patients approved by the U.S. Food and Drug Administration
Agents Year Endpoint Indication
Docetaxel 2004 OS
HRPC: with prednisone in androgen-independent (hormone-refractory) metastatic prostate 
cancer
Cabazitaxel 2010 OS
A microtubule inhibitor used in combination with prednisone, indicated for the treatment 
of patients with metastatic HRPC previously treated with a docetaxel-containing regimen
Sipuleucel-T 2010 OS
An autologous cellular immunotherapy indicated for the treatment of asymptomatic or 




A CYP17 inhibitor indicated for use in combination with prednisone for the treatment of 





Used with prednisone for metastatic castration-resistant prostate cancer before chemo-
therapy
Enzalutamide 2012 OS
An androgen receptor inhibitor indicated for the treatment of patients with metastatic 




Used for the treatment of patients with CRPC, symptomatic bone metastases and no 
known visceral metastatic disease
Enzalutamide 2014 OS/rPFS The treatment of patients with metastatic CRPC (who have not received chemotherapy)
CRPC, castration-resistant prostate cancer; HRPC, hormone-refractory prostate cancer; QOL, quality of life; OS, overall sur-
vival; rPFS, radiographic progression-free survival
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compared with mitoxantrone and prednisone, provided 
support for using this approach in patients with meta-
static, androgen-independent prostate cancer.
　In 2010, another taxane, cabazitaxel, became avail-
able.71) Cabazitaxel is a novel tubulin-binding taxane 
drug with antitumor activity in docetaxel-resistant can-
cers. In the TROPIC study, de Bono et al. reported the 
results of a comparison of the efficacy and safety of 
cabazitaxel plus prednisone with those for mitoxan-
trone plus prednisone in patients with metastatic CRPC 
with progressive disease after docetaxel-based treat-
ment. The median survival was 15.1 months in the 
cabazitaxel group and 12.7 months in the mitoxantrone 
group (as a control). The hazard ratio for death of the 
patients treated with cabazitaxel compared with those 
taking mitoxantrone was 0.70 (p<0.0001). Treatment 
with cabazitaxel plus prednisone had significant clinical 
antitumor activity, improving the overall survival in pa-
tients with metastatic CRPC whose disease has pro-
gressed during or after docetaxel-based therapy. Two 
ongoing trials (FIRSTANA and PROSELICA) are now 
being performed to evaluate two different doses of 
cabazitaxel (20 and 25 mg/m2) in the pre- and post-
docetaxel settings to assess whether dose reduction, 
often required because of myelotoxicity, affects the 
therapeutic response.72)
　One immunotherapy, sipuleucel-T, was approved 
based on the results of the IMPACT study in 2010.73) 
Sipuleucel-T is an active cellular immunotherapy, a 
type of therapeutic cancer vaccine, consisting of autolo-
gous peripheral blood mononuclear cells, including anti-
gen-presenting cells, that have been activated ex vivo 
with a recombinant fusion protein (PA2024). PA2024 
consists of a prostate antigen, prostatic acid phospha-
tase, that is fused to granulocyte-macrophage colo-
ny-stimulating factor, an immune cell activator. Sipuleu-
cel-T has shown evidence of efficacy for reducing the 
risk of death among patients with metastatic CRPC. In 
the sipuleucel-T group, there was a relative reduction 
of 22% in the risk of death compared with the placebo 
group (hazard ratio, 0.78; P=0.03). This reduction repre-
sented a 4.1-month improvement in median survival 
(25.8 months in the sipuleucel-T group vs. 21.7 months 
in the placebo group). Among patients with PSA assess-
ments after baseline, reductions of at least 50% on two 
visits at least four weeks apart were observed in eight 
of 311 patients (2.6%) in the sipuleucel-T group, com-
pared with two of 153 patients (1.3%) in the placebo 
group. The use of sipuleucel-T prolonged the overall 
months with zoledronic acid (hazard ratio 0.82; P=0.0002 
for non-inferiority; P=0.008 for superiority). More events 
of hypocalcaemia occurred in the denosumab group 
(13%) than in the zoledronic acid group (6%, P<0.0001). 
Osteonecrosis of the jaw occurred infrequently in both 
groups (2% vs. 1%; P=0.09). Therefore, denosumab was 
better than zoledronic acid for the prevention of skele-
tal-related events, and potentially represents a novel 
treatment option for patients with bone metastases 
from CRPC.
C. Agents to improve the overall survival
　Docetaxel was the first agent demonstrated to pro-
long the overall survival in CRPC patients. This agent 
was approved in 2004 and still plays an important role 
in the treatment of CRPC. The mechanism of action of 
taxanes seems to involve not only microtubule stabiliza-
tion and inhibition of tubulin function, but also both AR 
nuclear localization and signaling inhibition. There were 
two important trials that established the efficacy of 
docetaxel. One was TAX 327 conducted by Tannock et 
al.69) They showed that, compared with the patients in 
the mitoxantrone group, those in the group given 
docetaxel every three weeks had a hazard ratio for 
death of 0.76 (P=0.009 by the stratified log-rank test) 
and those given weekly docetaxel had a hazard ratio for 
death of 0.91 (P=0.36). The median survival was 16.5 
months in the mitoxantrone group, 18.9 months in the 
group given docetaxel every three weeks and 17.4 
months in the group given weekly docetaxel. Among 
these three groups, 32%, 45% and 48% of patients had 
at least a 50% decrease in the serum PSA level, respec-
tively (P<0.001 for both comparisons with mitoxan-
trone). When given with prednisone, docetaxel (given 
every three weeks) led to superior survival and im-
proved response rates in terms of pain, the serum PSA 
level and the patient quality of life, as compared with 
mitoxantrone plus prednisone. 
　The other trial was the SWOG9916 trial conducted 
by Petrylak et al.70) The median overall survival was 
longer in the group given docetaxel and estramustine 
than in the group given mitoxantrone and prednisone 
(17.5 months vs. 15.6 months, P=0.02 by the log-rank 
test). PSA declines of at least 50% occurred in 50% and 
27% of patients, respectively (P<0.001), and objective 
tumor responses were observed in 17% and 11% of pa-
tients with bidimensionally measurable disease, respec-
tively (P=0.30). The improvement in median survival of 
nearly two months by docetaxel and estramustine, as 
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cation and impairs both DNA binding to androgen re-
sponse elements and the recruitment of coactivators. It 
is orally available and induced tumor regression in 
mouse models of CRPC. Of the first 30 patients treated 
with enzalutamide in a Phase I/II clinical trial, 13 of 30 
(43%) showed sustained declines (by >50%) in the serum 
concentrations of PSA. Then, the AFFIRM trial was 
conducted as a phase 3, double-blind, placebo-controlled 
trial by Scher in the setting of CRPC after chemothera-
py.79) The median overall survival was 18.4 months in 
the enzalutamide group versus 13.6 months in the pla-
cebo group (hazard ratio for death in the enzalutamide 
group, 0.63; P<0.001). The superiority of enzalutamide 
over placebo was shown with respect to all secondary 
endpoints, including the proportion of patients with a 
reduction in the PSA level by 50% or more (54% vs. 2%, 
P<0.001), the soft-tissue response rate (29% vs. 4%, 
P<0.001), the QOL response rate (43% vs. 18%, P<0.001), 
the time to PSA progression (8.3 vs. 3.0 months; hazard 
ratio, 0.25; P<0.001), the radiographic progression-free 
survival (8.3 vs. 2.9 months; hazard ratio, 0.40; P<0.001) 
and the time to the first SRE (16.7 vs. 13.3 months; haz-
ard ratio, 0.69; P<0.001). Seizures were reported in five 
patients (0.6%) receiving enzalutamide. Therefore, en-
zalutamide was proven to significantly prolong the sur-
vival of patients with metastatic CRPC after chemo-
therapy, but is associated with a risk of seizures.
　In 2014, the results of the PREVAIL trial to develop 
new treatment options for patients with metastatic PCa 
who had not received chemotherapy, in whom the dis-
ease has progressed despite ADT were reported. This 
study was conducted by Beer et al. as a double-blind, 
phase 3 study.80) The co-primary endpoints were the 
radiographic progression-free survival and the overall 
survival, which were the same as in the COU-AA-302 
trial.76) The rate of radiographic progression-free surviv-
al at 12 months was 65% among patients treated with 
enzalutamide, compared with 14% among patients re-
ceiving placebo (81% risk reduction; hazard ratio in the 
enzalutamide group, 0.19; P<0.001). A total of 626 pa-
tients (72%) in the enzalutamide group, as compared 
with 532 patients (63%) in the placebo group, were alive 
at the data-cutoff date (29% reduction in the risk of 
death; hazard ratio, 0.71; P<0.001). The benefits of en-
zalutamide were shown with respect to all secondary 
endpoints, including the time until the initiation of cyto-
toxic chemotherapy (hazard ratio, 0.35), the time until 
the first SRE (hazard ratio, 0.72), the complete or partial 
soft-tissue response rates (59% vs. 5%), the time until 
survival among patients with metastatic CRPC, but no 
effect on the time to disease progression was observed, 
and the effects on PSA were limited.
　Abiraterone acetate is an oral steroid derivative used 
to suppress androgen production within the testes, ad-
renal glands and prostate by irreversibly inhibiting 
CYP17 (P450c17; C17, 20-lyase and 17α-hydroxylase). 
Abiraterone acetate affects both the classical and back-
door pathways of androgen biosynthesis.74) Using this 
agent, the serum testosterone level was reduced below 
the limit of detection. In the COU-AA-301 study, de 
Bono et al. evaluated whether abiraterone acetate pro-
longed the overall survival among patients with meta-
static CRPC who had received chemotherapy. The 
overall survival was longer in the abiraterone ace-
tate-prednisone group than in the placebo-prednisone 
group (14.8 months vs. 10.9 months; hazard ratio, 0.65; 
P<0.001). All secondary endpoints, including the time to 
PSA progression (10.2 vs. 6.6 months; P<0.001), progres-
sion-free survival (5.6 months vs. 3.6 months; P<0.001) 
and PSA response rate (29% vs. 6%, P<0.001), favored 
the treatment group.75)
　Furthermore, in the COU-AA-302 study, Ryan et al. 
reported the efficacy of abiraterone acetate in CRPC 
patients who had not received previous chemothera-
py.76) The co-primary endpoints were the radiographic 
progression-free survival and overall survival, which 
was based on a consensus among European experts in 
mCRPC to be appropriate primary endpoints for phase 
III clinical trials of CRPC.77) The median radiographic 
progression-free survival was 16.5 months with abi-
raterone-prednisone and 8.3 months with prednisone 
alone (hazard ratio for abiraterone-prednisone vs. pred-
nisone alone, 0.53; P<0.001). The overall survival was 
improved with abiraterone-prednisone (median not 
reached, vs. 27.2 months for prednisone alone; hazard 
ratio, 0.75; P=0.01) but did not cross the efficacy bound-
ary. Abiraterone-prednisone showed superiority over 
prednisone alone with respect to the time to initiation of 
cytotoxic chemotherapy, opiate use for cancer-related 
pain, PSA progression and the decline in performance 
status. Therefore, abiraterone acetate has a survival 
benefit for both chemotherapy-naïve and resistant 
CRPC patients.
　Enzalutamide (MDV3100) is a second generation 
non-steroidal anti-androgen developed by Tran et al. in 
2009.78) Enzalutamide binds to the AR with greater rel-
ative affinity than the clinically used anti-androgen bi-
calutamide, reduces the efficiency of its nuclear translo-
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Assessments of all main secondary efficacy endpoints 
also showed a benefit of radium-233 compared with pla-
cebo. Radium-223 was associated with low myelosup-
pression rates and few adverse events.
 
D. The current management of CRPC in the era of mul-
tiple agents that can prolong survival
　As shown above, during the past decade, multiple 
options for the treatment of CRPC that can achieve not 
only QOL improvement, but also survival benefit, have 
been introduced. Important clinical questions remain 
unclear; including which agent is the best, or what the 
best order or sequence is for these agents. Currently, 
there are no available data to prove the superiority of 
any of these new drugs compared to the others. Each 
study has had different patient eligibility criteria and 
background. Recently, updated clinical practice guide-
lines for CRPC recommend choosing agents based on 
the history of prior chemotherapy (docetaxel), the per-
formance status, state of metastasis and the patients’ 
symptoms.6,84,85) A summarized CRPC guideline from 
the American Urological Association is shown in Table 
4.84) The statements are presented in the guideline as 
Standards, Recommendations or Options. When suffi-
cient evidence existed, the body of evidence for a par-
ticular treatment was assigned a strength rating of A 
(high), B (moderate) or C (low). In the absence of suffi-
cient evidence, additional information was provided as 
Clinical Principles and Expert Opinions. There are 
PSA progression (hazard ratio, 0.17) and the rate of de-
cline of at least 50% in PSA (78% vs. 3%) (P<0.001 for all 
comparisons). Enzalutamide was also shown to signifi-
cantly decrease the risk of radiographic progression 
and death, and delayed the initiation of chemotherapy 
in patients with metastatic prostate cancer. The addi-
tional indication for use in the setting of CRPC before 
chemotherapy is just given to this agent in 2014.
　The newest agent approved for CRPC is radium-223. 
Radium-223 dichloride is a targeted alpha emitter that 
selectively binds to areas of increased bone turnover in 
bone metastases and emits high-energy alpha particles 
of short range (<100 μm).81) As a bone-seeking calcium 
mimetic, radium-223 is bound into newly formed bone 
stroma, especially within the microenvironment of os-
teoblastic or sclerotic metastases. The short path of the 
alpha particles also means that the toxic effects on adja-
cent healthy tissue, and particularly on the bone mar-
row, may be minimized.82) The ALSYMPCA study as-
sessed the efficacy and safety of radium-223 compared 
with placebo, in addition to the best standard of care, in 
patients with CRPC, bone metastases and no known 
visceral metastases, who had already received or were 
not eligible to receive docetaxel.83) Radium-223 signifi-
cantly improved overall survival compared to placebo 
(median, 14.0 months vs. 11.2 months; hazard ratio, 0.70; 
P=0.002). The updated analysis involving 921 patients 
confirmed the survival benefit of radium-223 (median, 
14.9 months vs. 11.3 months; hazard ratio, 0.70; P<0.001). 
Table 4 (a). A summary of the American Urological Association guideline for castration-resistant prostate cancer
Index 1 2 3
Symptoms - -, mild +
Metastasis - + +
Prior docetaxel - - -









observation with continued ADT (C) abiraterone+P (C)
Options
first-generation anti-androgens
(flutamide, bicalutamide, nilutamide) (C)
first generation androgen synthesis inhibitors
(ketoconazole+steroids) (C)
first-generation anti-androgens
















P.S., performance status; P, prednisone; ADT, androgen deprivation therapy; Ra-223, radium-223
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ter administrating 9.7 mCi (359 mBq) of FDG intrave-
nously. Transmission images were acquired for 5 min 
per table position, and emission images, for 3 min per 
table position. Images were corrected for attenuation, 
and standardized uptake values were calculated using 
a commercially available algorithm. In addition, whole-
body 67Ga (gallium citrate) scintigraphy was performed 
24 hr after administering 3.7 MBq/kg of 67Ga intrave-
nously. An MRI was performed with a 1.5 T supercon-
ducting magnet (Magneton Vision, Siemens Medical 
Solutions) using a body phased-array coil. The MRI se-
quences included a T1-weighted spin-echo (TR500/
TE15), fast spin-echo T2-weighted images (TR4000/
TE100) and enhanced spin-echo T1-weighted images 
(0.1 mmol/kg of intravenous gadoterate meglumine [Gd] 
[Magnescope, Guerbet]).
　Sarcoidosis is a systemic granulomatous disease of 
unknown origin involving multiple organs and tissues. 
It frequently affects the lung and hilar lymph nodes1), 
but muscular involvement can rarely occur. There are 
three main clinical types of muscular sarcoidosis : the 
acute myositic type, the atrophic type, and the nodular 
type2). We report a case of sarcoidosis with muscle in-
volvement diagnosed on FDG-PET.
Case Report
　A 54-year-old woman was hospitalized due to dysba-
sia. On examination, a palpable mass was detected on 
the lateral left leg. Blood tests showed remarkably ele-
vated erythrocyte sedimentation rate (33mm/hr).
　A whole-body PET was performed using an Advance 
PET scanner (Siemens Medical Solutuions)　45min af-
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　The PET showed increased uptake in the left leg 
(maximum standardized uptake value, 2.69) (Fig. 1), but 
the 67Ga scan showed no abnormal uptake (Fig. 2). The 
MRI revealed a donut-shaped lesion that was nearly 
Fig. 1.   A 54-year-old woman diagnosed with sar-
coidosis.
The coronal FDG-PET image shows FDG 
uptake in the left leg.
Fig. 2.   67Ga scintigraphy in a 54-year-old wom-
an. The 67Ga  scan shows no abnormal 
uptake in the either leg.
Fig. 3   T1 and T2 weighted and contrast-enhanced MRI of 
the left leg
(a) The T1-weighted axial image shows a do-
nut-shaped lesion that is nearly isointense to the 
muscle, with low signal intensity centrally
(b) T2-weighted axial image, same level. The lesion 
shows mildly increased in signal intensity compared 
to the surrounding muscle and low signal intensity 
centrally.
(c) On the contrast-enhanced T1-weighted axial im-
age, the lesion periphery shows enhancement, but 
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sensitivity of 18F-FDG PET (100%) in detecting cardiac 
sarcoidosis was significantly (P<0.01) higher than that 
of 67Ga scintigraphy (36%)7). In our case FDG PET 
showed increased uptake in the left leg, but  the 67Ga 
scintigraphy showed no abnormal uptake. Thus, 
18F-FDG PET appears to be a promising alternative to 
67Ga scintigraphy for evaluating the extent of extrapul-
monary sarcoidosis.
　In conclusion, our case shows that FDG-PET may be 
a more sensitive tool for evaluating the extent of muscle 
involvement in sarcoidosis compared to 67Ga scintigra-
phy.
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isointense to the muscle, with low signal intensity cen-
trally on the T1-weighted image and mildly increased 
signal intensity compared to surrounding musculature 
on the T2-weighted image. After administering Gd in-
travenously, the peripheral region of the lesion en-
hanced on the T1-weighted image, but central region 
did not (Fig. 3). 
　A muscle biopsy of the site revealed a noncaseating 
granuloma, confirming a diagnosis of sarcoidosis. 
Discussion
　Sarcoidosis is a chronic inflammatory disease of un-
known cause characterized histologically by noncaseat-
ing granulomas in affected tissues. Muscular sarcoidosis 
is a rare entity and is seen in approximately 6 % of pa-
tients with sarcoidosis3). Muscular involvement is usual-
ly asymptomatic. Muscles in the proximal the extremi-
ties are a frequently involved4).
　67Ga scintigraphy has been widely used in studies of 
sarcoidosis. These studies describe a typical pattern of 
67Ga uptake in sarcoidosis cases known as a “lambda” 
pattern of mediastinal lymphadenopathy, which reflects 
the right paratracheal and bilateral hilar involvements5).
　The FDG uptake increases when the metabolic activ-
ity is increased by inflammatory cells. In sarcoidosis, 
macrophages are activated and play an important role 
in granuloma formation; this may explain the strong 
FDG uptake in granulomatous lesions of sarcoidosis5). 
Muscule involvement on FDG PET compared to 67Ga 
scanning has only been reported once previously6).
　Okumura et al. compared 18F-FDG PET to 67Ga scin-
tigraphy in 11 patients with cardiac sarcoidosis. The 
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Case report
　A 48-year-old man presented to our hospital with 
pain in the finger, toe, and ankle joints. He had a history 
of hypertension. Two years prior, he had had painful 
swelling and erythema of the second finger of left hand, 
which resolved spontaneously. One and one half years 
later, he had recurrent swelling and erythema of the IP 
joint of the right first finger, the MTP joint of the left 
third toe, and the left medial malleolus. He had been 
seen by an Internist, a Dermatologist and an Orthope-
dist. Gouty arthritis or infectious arthritis was consid-
ered with negative rheumatoid factor (RF) and he was 
Introduction
　Psoriatic arthritis can present as a complication of 
psoriasis. The diagnosis of psoriatic arthritis is easily 
made when the skin lesions of psoriasis are present, but 
it is difficult to diagnose when the arthritis precedes the 
appearance of the skin lesions. Some studies have 
shown that arthritis preceding the appearance of the 
skin lesions occurs in 15% to 30% of cases1～3).　This 
case was additionally difficult as the arthritis preceded 
the skin lesions by two years.
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　We present a case of psoriatic arthritis preceding the appearance of skin manifestation. A 48-year-
old man presented to our hospital with pain in the finger, toe, and ankle joints. The erythematous and 
swollen joints were 3 joints, and the distribution of them is asymmetrical. The antibodies referring 
rheumatoid arthritis (RA) were negative. Two years had gone from the onset of joints pain until the 
appearance of the skin lesions, helping of diagnosis of the psoriatic arthritis. Although the diagnosis of 
psoriatic arthritis is easily made when the skin lesions of psoriasis are present, it is difficult to diagnose 
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rical oligoarthritis with negative RF even in the absence of typical skin lesions as the possible diagno-
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left MTP joint had appeared. In addition, a one to two 
cm patch of erythema had appeared on the left upper 
arm. A Dermatologist was consulted for a possible diag-
nosis of psoriasis. As it was not the typical skin lesion of 
psoriasis, a biopsy was not done. Moreover, although a 
whole body and nail examination was performed at that 
time, no typical rash or nail changes of psoriasis were 
found. One month later, swelling of the MTP joints of 
the second and third toe, and the dorsum of left foot 
was present. Laboratory findings showed resolution of 
the hyperuricemia. We discontinued allopurinol due to 
poor response. The patient reported that a scaly rash 
appeared for one day during this period. We therefore 
consulted the dermatologist again. He did not think that 
this was psoriasis, but he did find another lesion with 
erythema and scale on the scrotum (Fig 2 A), and a bi-
opsy was done. At the same time, we also consulted 
with a Rheumatologist. He diagnosed the arthritis as 
early RA with synovial inflammation by joint ultraso-
nography. Methotrexate was initiated. Ten days later, 
the skin biopsy was reported as consistent with psoria-
treated with allopurinol and levofloxacin. He did not 
improve, so he was treated with loxoprofen sodium 
120mg/day on his initial visit to our hospital.
　On physical examination, the right first IP joint, the 
left third MTP joint, and the medial malleolus of left 
ankle were swollen and erythematous (Fig1 A,B,C), but 
other joints were unremarkable. The laboratory find-
ings showed mild liver dysfunction, hyperuricemia, and 
hyperlipidemia. C-reactive protein and erythrocyte sed-
imentation rate were slightly elevated. RF, anti nuclear 
antibody and anticyclic citrullinated peptide were neg-
ative. On X-ray, boney erosion and narrowing of the 
joint spaces were not present. According to  ACR/EU-
LAR　2010 criteria4), the score of 5 points did not meet 
criteria for RA (more than 6 points).
　Although a firm diagnosis was not made at the first 
examination, we began to treat as gout with allopurinol 
200mg/day and loxoprofen sodium 180mg/day. One 
month later, the painful swelling and erythema of the 
right first IP joint and the left third MTP joint had im-
proved, but new swelling and erythema of the second 
Fig. 1. A:  The IP joint of the first finger of the right hand was swollen and erythematous. B: The MTP joint of the 
third toe of the left foot was swollen and erythematous. C: Expansion of B
A B
C
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sis (Fig 2 B). We ultimately diagnosed his symptoms as 
psoriatic arthritis with skin psoriasis (2 points), negative 
rheumatoid factor (1 point) ,and dactylitis (1 point) ac-
cording to the new CASPAR criteria (more than 3 
points being psoriatic arthritis)5).
Discussion
　Psoriatic arthritis is a severe erosive arthritis associ-
ated with psoriasis.  It has the characteristics of asym-
metrical oligoarthritis, especially arthritis of distal joints, 
negative RF, skin psoriatic lesions and nail lesions (pit-
ting, onycholysis, and oil staining). 
　This patient had asymmetrical oligoarthritis and neg-
ative RF, but he did not have skin lesions, arthritis of 
distal joints or nail changes. Diagnosis was delayed as 
the patient had no skin lesions at the first presentation, 
and did not develop typical skin lesions until two years 
after arthritis onset. Typical skin lesions are the key 
finding in the diagnosis of psoriatic arthritis, but arthri-
tis preceding the appearance of skin lesions occurs in 15 
to 30% of psoriatic arthritis cases according to the liter-
ature, making this diagnosis difficult in these cases. In 
addition, psoriatic arthritis can simulate rheumatoid ar-
thritis or gout. Thus, we should exclude both diseases 
before making the diagnosis of psoriatic arthritis.
Conclusions
　We presented a case of psoriatic arthritis preceding 
the typical skin lesions. It is necessary to follow up 
asymmetrical oligoarthritis with negative RF even in 
the absence of typical skin lesions, as the diagnosis may 
be psoriatic arthritis.
Fig. 2. A:  Erythema accompanied by scale on the scrotum. B: Pathology of the scrotal lesion; epidermal hyperplasia 
that is regular or uniform in degree, parakeratosis are seen.
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１位 米国 3314 米国 3695 米国 2677
２位 イングランド 920 イングランド 1484 イングランド 873
３位 カナダ 377 カナダ 511 カナダ 462
４位 オランダ 277 オランダ 502 ドイツ 343
５位 フランス 274 フランス 432 フランス 300
・ ・ ・
・ ・ ・

































































1位 2位 3位 4位 5位 圏外
全分野 英国 中国 ドイツ カナダ フランス 6位 日本
13.3 12.4 12.3 11.8 8.1 7.1
化学 中国 ドイツ 英国 日本 フランス
17.0 11.0 8.7 6.8 6.6
材料科学 中国 韓国 ドイツ 英国 日本
21.2 12.2 9.1 7.8 6.6
物理学
宇宙科学
ドイツ 英国 フランス 中国 イタリア 6位 日本
21.6 18.1 14.9 13.2 10.7 10.6
工学 中国 韓国 カナダ 英国 ドイツ 8位 日本
18.8 10.3 9.3 6.4 6.1 4.9
臨床医学 カナダ 英国 ドイツ イタリア 中国 7位 日本

























































































































































































































平均 5.85 5.38 5.35 5.42 5.47 5.59 5.49 5.79
偏差 2.54 1.91 1.84 1.86 1.77 1.73 1.74 1.82
最小 1.68 2.77 2.51 3.05 2.79 2.93 2.87 2.57
最大 15.56 10.61 11.78 10.89 10.70 10.42 10.58 10.52
最大/最小 9.3 3.8 4.7 3.6 3.8 3.6 3.7 4.1






















































































































































































































































税 低負担 中負担 高負担
社会保障 低福祉 中福祉 高福祉
再分配効果 効果小 効果中 効果大
格差
経済格差 大きい 中程度 小さい
男女格差 実力主義 男性中心 平等主義











































































































































































（下位職階を基準とした年齢調整） Sekine et al, Soc Sci Med 2009 
スライド15












































































































































Sekine et al, Soc Sci Med 2009 
職階高い人と基準とした不健康に対する年齢調整オッズ比
スライド18
1.0 1.0 1.2 1.0 
1.7 
2.0 











1.0 1.1 0.9 1.0 












































































































目標： 一生涯の健康 方法： 栄養重点の健康づくり、健診（2次予防）
• 第２次国民健康づくり対策 （1988年～） ＝ アクティブ80ヘルスプラン
目標： 80歳でも社会参加 方法： 運動重点の健康づくり、指針策定




• 第４次国民健康づくり対策 （2013年～） ＝ 健康日本２１（第２次）






































































グループＡ 旧帝大含む大都市総合大学： 東京大など13大学 0.331
グループＢ 医学部なしの理系総合大学： 東工大など13大学 0.431
グループＣ 医学部なしの文系総合大学： 一橋大など8大学 0.570
グループＤ 医系大学： 東京医歯大など4大学 0.168
グループＥ 教育系大学： 学芸大など11大学 0.609
グループＦ 大学院大学： 政策研究大学院大学など４校 0.257
グループＧ 医学部ありの地方総合大学： 富山大など25大学 0.317











































































































































五福 杉谷 病院 高岡
P < 0.001























































































































就 任 寄 稿
顔と身体の認知
堀　悦郎
Perception of face and body
Etsuro HORI





て担っている。顔認知の中心的なシステムは，紡錘状回顔領域（fusiform face area; FFA），後頭葉顔
領域（occipital face area; OFA）および上側頭溝で構成されている。これらに加え，頭頂溝，聴覚領域，
扁桃体および側頭葉先端部などが顔認知システムに含まれる。一方，身体認知の中心的システムは，外




Key words: face perception, body perception, brain function











































































領 域 があることから，この 領 域 を 紡 錘 状 回 顔 領 域









の顔関連領域は，後頭葉顔領域（occipital face area; 








いる19, 26, 2７）。OFAから誘発されるP 1 もまた，FFAから
誘発されるN1７0と同様に，顔以外の視覚刺激と比べる
と顔刺激で有意にその振幅が大きくなり，顔刺激を倒立
呈示するとその振幅が減少する23, 25, 26, 28）。しかし，反応
時間，正答率などの行動学的パラメータと強い相関があ




































































occipital face area. FFA; fusiform face area, 
STS; superior temporal sulcus上 側 頭 溝, EBA; 
extrastriate body area, FBA; fusiform body area, 
IPL; inferior parietal lobe下頭頂小葉, rIPL; rostral 
inferior parietal lobe下 頭 頂 小 葉 吻 側 部, vPMC; 
ventral premotor cortex 腹 側 運 動 前 野, pIFG; 
posterior inferior frontal gyrus下前頭回後部．（文
献37を改変）




















































反 応 潜 時 が190ミリ 秒 前 後 の 陰 性 の 事 象 関 連 電 位
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Update of management of childhood asthma
Yuichi Adachi










　There has been a big change in the management of childhood asthma during the last 30 years. 
Because of the successful treatment, most asthmatic children have not experienced severe exacerbations 
in these days, but their symptoms are still not controlled completely.  To aim better control of asthma, 
evaluation of airway inflammation, treatment with proper anti-inflammation drugs, and assessment of 
obstacles such as poor adherence, comorbidities, and environmental factors is  essential.  Further 
understanding of the environmental factors associated with the inception of asthma might provide 
future treatment strategies.
Key words: childhood asthma, control level
足立：「最近の小児気管支喘息診療よりよいコントロールレベルを目指して」 51












（ 4 - 5 歳），小 学 生（ 6 - ７ 歳），中 学 生（13-14歳），高




























































明らかな喘息発作 2 なし なし 1 回/月以上
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喘 息 発 症 を 有 意 に 減 らすことができたとの 報 告 もあ
る15）。
　また，近年越境汚染などの言葉で表されるように中国
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New niche of the basophil in the immune-network and the role of Swiprosin-１
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　Swiprosin-1 is a relative new intracellular protein reported for the first time in 2004. It has been 
suggested to associate with intracellular signaling in T-cells and lifespan of B-cells from the past results 
of research, but the roles in basophils are still unknown. The basophils play a role of type-I allergic 
reaction with mast cells, and suggested one of the commanders. From our results using the rat 
basophilic leukemic cells (RBL-2H3 cell line) as a model, Swiprosin-1 is more likely to cause degranulation 
in type-I allergic reaction. Further work is necessary to elucidate the roles of Swiprosin-1 for the 
treatment of type-I allergic reaction.


























タンパク質は，EF-hand domain contain-ing protein D2
（EFhd2）とも呼ばれている。分子量が2７-33kDaであり，
る。」とされた（図1A）。ところが2000 年 代 以 降 は，





























































































































図 3 　Swiprosin- 1 の分子構造モデル
　Swiprosin-1はN末側から一つのproline richドメイン(PR），



















順 次 カスケードを 膨 らませて 行 くことが 知 られてい
る1７～20）。
　我々は，免疫蛍光染色によって，Swiprosin-1とFcεRI










ができる 状 態 にあることが 分 かった。この 結 果 は，
Swiprosin-1がFcεRIの初期シグナルにおいて何らかの関
連を持っている可能性を示す。








な 解 析 を 行った。すなわち，Swiprosin-1のノックダウ
ン実験より，Swiprosin-1は，その独自の分子構造を介
してシグナル分子であるSykとPLC-γ2を標的として相互
作 用 することを 示 した。 この 相 互 作 用 により，
Swiprosin-1は，B細胞抗原受容体（BCR）シグナル由来
の細胞内カルシウム起動に決定的な役割を担ってい




























造 体 である。生 化 学 的 には，別 名Detergent-resistant 










集合したFcεRIは，LynなどのSrc family kinase （SFK）
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いるLynやSykが同定されるのではないかと予想したが，
高いスコアで該当したタンパク質は，Vimentinであっ


























































合 していた。特 に 約50 kDaのタンパク 質 のチロシンリ
ン酸化は抗原刺激によって顕著に増加し，Swiprosin-1




図 5 　Swiprosin- 1 会合タンパク質の探索
A. RBL-2H3（1.0 ×107 cells/sample）にIgE（抗DNPモノク
ローナル 抗 体）を 添 加 した 後，over night培 養 し，抗 原
（DNP）で 1 時間刺激した。刺激後，細胞を500μLの細胞





激 の － と ＋ レーンから 切 り 出 し，MALDI TOF-MSによる
Peptide mass fingerprintを行った。写真は，解析に用いた富
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図 6 　RBL-2H3における Swiprosin- 1 とVimentinの局在
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Nursing students’ feelings of personal growth in Clinical Practice in Psychiatric Nursing
Izumi TANAKA，Hayato HIGA，Keiko YAMADA












　The purpose of this study was to clarify the feelings of personal growth in students participating in 
Clinical　Practice　in　Psychiatric　Nursing, and to obtain suggestions for more effective instruction 
of teaching technique. A content analysis was conducted from training and interview records of ７8 
nursing students. The results showed feelings of personal growth in Understanding how to comprehend 
patient’s mental symptoms and make assessments, Understanding patients’ overall presentations, 
Changing student’s image of psychiatry, Understanding the characteristics of mental health nursing, 
Nursing practices, Broadening perspectives, Use of communication techniques, Communicating with 
patients while making observations, Getting closer to patients’ feelings, Patient involvement with 
consideration of their individual status and needs, Acquisition of conversational ability, and 
Assertiveness, propriety, sense of responsibility, and cooperation with respect to clinical training. The 
above suggests the need to further strengthen the meaning students find in their experience from 
process records in the psychomotor and emotional domains.
Key words: nursing students, feelings of personal growth, clinical practice in psychiatric nursing





























































































































































































































































































































































































































































































































































































































































































































A case of intracranial lipoma mimicking basilar artery dissection
Yuuichi KAMISAKI, Gakuto TOMIZAWA, Hideto KAWABE,
Minoru MORIJIRI, Rie IKEDA, Kyo NOGUCHI






　We present a case of intracranial lipoma mimicking basilar artery dissection. Intracranial lipomas are 
rare congenital malformations. They tend to specific locations within the brain. Fat-saturated T1-
weighted image is helpful in differentiating lipoma from intramural hematoma of dissecting artery.
Key words: intracranial lipoma, basilar artery dissection, MRI
図 1 　MRI T 2 強調像　橋脳に古い脳梗塞巣を認める。















強調像，T 2 強調像（図 3 ）にて高信号を呈する腫瘤性





図 3 　 MRI T 1 強調像（a），T 2 強調像（b）　脳底動脈に接
する高信号を呈する病変を認める。





























1 ） Truwit CL., Barkovich AJ. Pathogenesis of intracranial 
lipoma: an MR study in 42 patients. AJR 1990; 155: 
665–6７4
2 ） Yildiz H., Hakyemez B., Koroglu M., et al: Intracranial 
lipomas: importance of localization. Neuroradiology 
2006; 48; 1–７
3 ） Sasaki H., Yoshida K., Wajamoto H., et al: Lipomas of 
frontal lobe. Clin Neiurol Neurosurg 1996; 98: 2７–31
4 ） Futami K., Kimura A., Yamashita J. Intracranial lipoma 
assosciated with cerebral saccular aneurysm: case re-


































































A case of the manhood osteosarcoma arising from the lateral epicondyle of the femur
Masahiko KANAMORI１, Kayo SUZUKI２, Taketoshi YASUDA２, Ayano TOKUNAGA２, Tomoatsu KIMURA２
1Department of Human Science (1), University of Toyama











　We have performed limb-salvage procedures with endoprosthesis in a manhood osteosarcoma case 
arising from lateral epicondyle (35-year-old male). The tumor massively existed in metaphysis and 
epiphysis of the distal femur, because the growth plate had closed. The tumor was removed with wide-
margin, and was not recurred. But the patient undertook the removal of a lung metastasis 6.3 years 
after the initial surgery. This primary tumor was suggested to originate from the remnant of the 
growth-plate, because the tumor had the abundant chondromatous component and its location was 
concomitant with the growth-plate (physis).
Key words: osteosarcoma, lateral epicondyle, growth-plate
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した。メソトレキセート（MTX: 12-14g） 2 回，シスプ
ラチン（CDDP: 120mg）／アドリアマイシン（ADM: 





















年 5 か月後に右肺下葉に転移（24×12 mm）を生じ（図
図 1 　術前MRI前額断像
図 1. 術前MRI 前額断像 
T1強調像 T2強調像 
図 2 b　手術時の病理学的所見（軟骨形成の多いところ）図2ｂ.㻌 手術時の病理学的所見 
（軟骨形成の多いところ） 




図 2 a　手術時の病理学的所見（類骨形成の多いところ）図2a.㻌 手術時の病理学的所見 
（類骨形成の多いところ） 
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　平成23年12月22日に，当時医学科 3 年次生（現医学科 6 年次生）に対し，大学院教務委員長の二階堂教授
から，①研究医養成プログラムを新たに設けること，②修了要件については検討中であるが，所属講座で研
究活動を継続し，一定の研究成果を上げることが要件となる予定であることを説明しました。平成23年12月




















　血小板由来増殖因子（platelet derived growth factor, PDGF）は当初，間葉系細胞のmitogenとして同定
されたが，我々は神経保護作用を併せ持つことを報告してきた（Iihara et al., 1994 and 1996; Ishii et al., 
2006; Zheng et al.,  2010）。我々は，生後タモキシフェン投与により全身性にPDGF β 受容体（PDGFR-β）
のconditional knockoutを誘導するマウスに中大脳動脈閉塞による脳梗塞を施し，病変がコントロールマウ
スより大きく，さらに修復における血管の成熟が遅延すること，アストロサイトによるグリア瘢痕形成が遅







　PDGFR-β遺伝子のexon 4 - ７ の両側にloxPシークエンスを挿入したマウス（PDGFR-β flox/flox）と，ER-TM 
Creトランスジェニックマウス（Cre-ERTM+/−）との 交 配 によって 得 られるCre-ERTM+/− PDGFR-βflox/floxマ
ウスを 用 いた。コントロールとして 同 腹 仔Cre-ERTM−/− PDGFR-βflox/floxマウスを 用 いた。Cre-ERTM+/− 
PDGFR-βflox/floxマウスより採取したアストロサイトに 1 μM 4 OH-タモキシフェン（TMX）を48時間培養液
に加えることにより，PDGFR-β knockoutを誘導した。以下はβ KOと記す。Cre-ERTM−/− PDGFR-βflox/flox




　Western blotによるPDGFR-β 蛋白質の発現は，β FLアストロサイトでは明瞭に認められたが，β KOでは
殆ど検出できない程度にまで減少した。PDGFR-α蛋白質の発現はβ FLとβ KOで同様に認められ，PDGFR-β 
KOの影響はないことを確認した。β KO アストロサイトのPDGFR-β mRNA発現は，β FL の29.8%まで減少
した。PDGFR-αのmRNA発現にはβ KOとβ FLで有意差は見られなかった。
2 ．増殖能の検討
　DMEM/F12に10% FBSまたは50 ng/ml PDGF-AAあるいはPDGF-BBを加えた培養液にてアストロサイ
トの増殖を比較検討した。β FLとβ KOにていずれも低細胞密度培養（500 cells/ml）ではPDGF-AAが，高
細胞密度培養（5,000 cells/ml）ではFBSが最もアストロサイトの増殖能を増加させた。低細胞密度（500 
cells/ml）で培養した場合は，FBS，PDGF-AA, PDGF-BB投与下のすべてにおいてβ KOの増殖能は β FLよ
り著明に低下した。高細胞密度（5,000 cells/ml）で培養すると，有意差はあるもののその差は縮小した。 
3 ．遊走能の検討
　高密度培養ではβ FLとβ KOの増殖能の差は縮小することがわかったので，アストロサイトを 1 ×105 






を分解し，神経細胞を保護する作用がある（Fernandez-Fernandez et al., 2012）。ROSの一つである過酸化















ること（Zheng et al., 2010），血管周皮細胞に発現し脳傷害後修復反応時において血管成熟作用を促進する
こと（Shen et al., 2012）を報告してきた。本研究により，PDGFR-βはアストロサイトに発現し，増殖，遊走，
抗酸化作用を増強させることが新たに示唆された。我々は脳梗塞後にPDGF-βの発現が増加することを過去








織 因 子（Tissue factor; TF）， プラスミノゲンアクチベーターインヒビター 1 （plasminogen activator 
inhibitor- 1 ，PAI- 1 ）の血液凝固関連因子の発現誘導を介して凝固反応を促進する。この細胞応答には，
トロンビン受容体であるprotease- activated receptor （PAR）を介することが明らかにされている。PARは
プロテアーゼで活性化される七回膜貫通型G蛋白共役受容体で，PAR- 1 ，PAR- 2 ，PAR- 3 ，PAR- 4 の 4
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材料および方法
　ヒト肝癌細胞株HepG 2 とHuh ７ は3７℃、 5 %CO2条件下で培養した。培養液にはウシ胎児血清（FBS）
10%， ペニシリン100U/mL， ストレプトマイシン100U/mLを 含 むDulbecco’s modified Eagle’s medium
（DMEM）を使用した。PAR- 1  mRNAの発現は定量的RT−PCR（プライマー : センス 5 ’- TTTGAATT
CATGGGGCCGCGGCGGCTGCTGCTG- 3 ’，アンチセンス 5 ’- TTTCTCGAGAGTTAACAGCTTTTTGT
ATATGCT- 3 ’）， PAR- 4  mRNAの発現は定量的RT-PCR（プライマー :センス 5 ’- TTTGAATTCATGTG
GGGGGCGACTGCTCCTG- 3 ’ アンチセンス 5 ’- TTTCTCGAGCTGGAGCAAAGAGGAGTGGGGT- 3 ’），
PAR- 1 蛋白質産生はPAR- 1 特異的抗体（R&B Systems,米国）を用い，蛍光組織免疫染色法とウエスタン
ブロット法にて解析した。HepG 2 とHuh ７ にトロンビン（牛血漿）を添加し，刺激前後におけるTF発現を
センス 5 ’- CCCAAACCCGTCAATCAAGTC - 3 ’、 アンチセンス 5 ’- CCAAGTACGTCTGCTTCACAT 
- 3 ’，PAI- 1 発 現 を セ ン ス 5 ’ -  ACCGCAACGTGGTTTTCTCA - 3 ’， ア ン チ セ ン ス 5 ’ -　
TTGAATCCCATAGCTGCTTGAAT - 3 ’をプライマーにして定量的PCRで解析した。さらに細胞を不可逆
的トロンビン阻害剤PPACKで30分間前処理した後，トロンビン（20 U/mL）刺激後 2 時間におけるTF，
PAI- 1 発現を解析した。
結　果
　肝がん細胞株HepG 2 細胞とHuh ７ 細胞は，RT-PCRにてPAR- 1 とPAR- 4  mRNAをともに発現している
ことを確認した。また，ウエスタンブロット法により，PAR- 1 とPAR- 4 のタンパク質産生も確認した。さ
らに，免疫染色法により，両細胞とも細胞質および細胞膜に局在することを明らかにした。ウエスタンブ
ロット法ではHuh ７ 細胞に比べてHepG 2 細胞の蛋白質発現量が多く，免疫染色においても，HepG 2 細胞で
はPAR- 1 が細胞質，細胞膜に強く発現しており，ウエスタンブロット法による結果と一致していた。
　次に，培養上清中にトロンビン（ 0 ，5, 10, 50 U/ml）を添加し 2 時間刺激したところ，TF，PAI- 1 とも
に，mRNAの発現量がトロンビン濃度依存的に有意に増加（10 U/mlトロンビン刺激でTF mRNA発現は 2
倍増加，PAI- 1  mRNA発現は1.5倍増加，50 U/mlトロンビン刺激でTF mRNA発現は 4 倍増加，PAI- 1  
mRNA発現は 6 倍増加）した。また，PPACK（ 1 μM）で前処理後（30分間），トロンビン（20 U/ml）刺
激 2 時間後トロンビンによるTFおよびPAI- 1  mRNA発現量の増加が抑制されること（TF：35％発現減少，
PAI- 1 ：38％発現減少）を認めた。
考　察
　肝がん細胞株HepG 2 細胞とHuh ７ 細胞において，トロンビン受容体PAR- 1 とPAR- 4 ともに発現してい
ることが明らかになった。PAR- 1 は，N末側の細胞外ドメインにトロンビン結合部位を有するため，他の
プロテアーゼよりトロンビンで強く活性化が生じる。一方，PAR- 4 はヒルジン様ドメインを欠いており，























1 ） Cottrell GS., Coelho AM., Bunnett NW.: Protease-activated receptors: the role of cell-surface 
proteolysis in signalling. Essays Biochem. 38: 169-83, 2002.
2 ） Nakanishi-Matsui M., Zheng YW., Sulciner DJ., Weiss EJ., Ludeman MJ., Coughlin SR., et al.: PAR 3 is 
a cofactor for PAR 4 activation by thrombin. Nature. 404: 609-13, 2000.
3 ） Kakarala KK., Jamil K.: Screening of phytochemicals against protease activated receptor 1 (PAR 1), a 
promising target for cancer. J. Recept. Signal Transduct. Res. 9: 1 -20, 2014.
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Differential effects of citrate versus PPACK anticoagulation on measured platelet inhibition by 
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ラット海馬歯状回in vivo LTPにおける再固定化過程
榎本　洸　生化学講座（指導：井ノ口　馨教授）














　0.1 Hzによる再刺激直後にanisomycinを脳室投与すると 2 日後においてanisomycin群とPBS群に有意差が
みられた。また， 2 日後においてanisomycin群と再刺激なし＋anisomycin群の間に有意差がみられた。0.1 
Hzによる再刺激はその後のLTP保持にタンパク合成を必要とすることがわかった。 8  Hzによる再刺激直後
にanisomycinを脳室投与すると 1 日後， 2 日後， 3 日後いずれにおいてもanisomycin群とPBS群の間に有意
差がみられた。また，anisomycin群と再刺激なし＋anisomycin群の間に 1 日後， 2 日後， 3 日後いずれに
おいても有意差がみられた。 8  Hzによる再刺激はその後のLTP保持にタンパク合成を必要とすることがわ
かった。200 Hzと400 Hzによる再刺激直後にanisomycinを脳室投与すると， 1 日後， 2 日後， 3 日後のい
ずれにおいてもPBS群との間に有意差はみられず，200 Hzと400 Hzは再固定化を誘導しないことがわかっ
た。再固定化に最も有効な刺激頻度は 8  Hzであった。anisomycin群と再刺激なし＋anisomycin群の間で有
意差があり，PBS群と再刺激なし＋anisomycin群の間に有意差がなかったことは再活性化条件下でのみLTP
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える影響を調べた。LTP誘導後，最も再活性化に有効であった 8  Hzによる再刺激を行い，直後にCPP，
saline，CPP＋anisomycinを脳室投与した。 1 日後， 2 日後， 3 日後に集合spikeを測定すると，再刺激 2 日
後にCPP群とsaline群の間に有意差がみられた。また，CPP群と再刺激なし＋CPP群の間にも有意差がみら
れた。 8  Hzによる再活性化後LTPを保持するにはNMDA受容体が必要であることがわかった。さらに，
CPP＋anisomycin群はsaline群と 1 日後， 2 日後， 3 日後において有意差がみられ， 8  Hzによる再活性化
後のanisomycinによるLTP保持の阻害はCPPにより阻害されず，CPPは不安定化を阻害していないことがわ
かった。
　ラットにおいて学習の際に観察され，θ波に分類される 8  Hzが再固定化に有効であったことは生体内に
おいて再固定化にθ波が重要な役割を持っていることが示唆される。今後さらに再固定化に必要なメカニズ
ムが解明されると，記憶の想起が関与するPost Traumatic Stress Disorder（PTSD）の治療につながるこ
とが期待できる。




富んでいる。例えば大脳皮質では，興奮性シナプス後電位（excitatory postsynaptic potential: EPSP）は0.01 















めの細胞の数理モデルとして “Multi-timescale  adaptive threshold（MAT）neuron model” を採用した。
































ml存在下で培養し，得られた 6 個のプラークから 6 つのウイルス（ 1 ～ 6 ）をクローニングした。
　それぞれのウイルス株について，TKをコードする領域であるUL23のcoding DNA sequence（cds）を含
む配列をPCRによって増幅し，塩基配列を決定した。
　各 株 について， アシクロビル（ACV）， ペンシクロビル（penciclovir，PCV）， イドクスウリジン
（idoxuridine，IDU）を 用 い，プラークアッセイ 法 による 薬 剤 耐 性 試 験 によって50%阻 害 濃 度（half 
maximal inhibitory concentration，IC50）を決定した。
結　果
　分離株 6 株中の内 5 株（ 1 ， 2 ， 3 ， 4 ， 6 ）はACV及びPCVに対し比較的高いIC50を示し，その内の 2
株（ 1 ， 6 ）は加えてIDUに対しても非常に高いIC50を示した。
　分離株 6 株のUL23における塩基配列を決定し，それぞれの株にポイントミューテーションが存在するこ
とを確認した。感受性が顕著に低下した株（ 1 ， 2 ， 3 ， 4 ， 6 ）は，UL23中のデオキシチミジンに結合
する領域上にポイントミューテーションが，さらに 1 と 6 の株には加えてフレームシフトによるナンセンス
変異が起きていることを確認した。
考　察
　UL23 cdsにおいて，G stretchと呼ばれるグアニンが 4 個以上連続する領域で起こっている変異の頻度と，
それ以外の領域において起こっている変異の頻度を，フィッシャーの直接確率計算法によって検討した。前
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腹部　肝を 3 ㎝，脾を 3 ㎝触知。
皮膚　両上肢に点状出血斑散在。
検査所見　WBC 2,７00， Hb 10.8， Plts 1.4万，AST 410， ALT 111, LDH 2909， CRP 0.44， Ferritin 12122， 尿






















　単純ヘルペスウイルス 2 型（herpes simplex virus- 2 ，HSV- 2 ）単純ヘルペスウイルス 2 型（HSV- 2 ）
による性器ヘルペスの治療にはアシクロビル（aciclovir， ACV）アシクロビル（ACV）などが用いられて











治療を受けている患者（ACV治療前：n = 23，ACV治療後再発：n = 16，ACV抑制療法中：n = 11）から





3 ．分離ウイルスの感受性（half maximal inhibitory concentration; IC50）測定



























The liver in itai-itai disease (chronic cadmium poisoning): Pathological 
features and metallothionein expression
馬場　逸人　病理診断学講座（指導：井村　穣二教授）
　Cadmium is a highly hepatotoxic heavy metal，which is widely dispersed in the environment. Acute 
cadmium hepatotoxicity has been well studied in experimental animals; however, effects of prolonged 
exposure to cadmium doses on the liver remain unclear. In the present study, to evaluate chronic 
cadmium hepatotoxicity，we examined specimens from cases of itai-itai disease，the most severe form of 
chronic cadmium poisoning. We compared 89 cases of itai-itai disease with 2７ control cases to assess 
cadmium concentration in organs. We also examined 80 cases of itai-itai disease and ７0 control cases for 
histopathological evaluation. In addition, we performed immunohistochemistry for metallothionein，which 
binds and detoxifies cadmium. Hepatic cadmium concentration was higher than cadmium concentration 
in all other organs measured in the itai-itai disease group，while it was second highest following renal 
concentration in the control group. In the liver in the itai-itai disease group, fibrosis was observed at a 
significantly higher rate than that in the control group. Metallothionein expression was significantly 
higher in the itai-itai disease group than in the control group. Prolonged exposure to low doses of 
cadmium leads to high hepatic accumulation, which can then cause fibrosis; however, it also causes high 







小板由来増殖因子受容体-β（以下platelet derived growth factor-β，PDGFR-β）が神経細胞新生や生存に関
与することを示唆する知見が蓄積されつつある。我々は以前の研究でPDGFR-βの発現を抑制した神経幹細






　PDGFR-β遺伝子のExon 4 ～ ７ 領域をLoxP配列で挟んだ塩基配列を持つフロックマウス（以下flox，FL）
をコントロールマウスとし，このコントロールマウスと，Nestin promotor/enhancer遺 伝 子 の 下 流 にCre 
recombinaseをコードする遺伝子を挿入したNestin-Cre マウスを高交配させることによって，Nestin発現神
経上皮細胞由来細胞におけるPDGFR-βの発現が抑制させたノックアウトマウス（以下knockout，KO）を用









　実験①において，同じ日齢のFLと比較してKOは，P 1 ，P28のいずれにおいても， PDGFR-βのmRNAの





齢 のFLと 比 較 してKOは，P 1 において 神 経 細 胞 のマーカーであるMicrotubule-associated protein 2
（MAP 2 ）のmRNAの発現が抑制されたが，P28に関しては有意差を認めなかった。同じジェノタイプの
P 1 と 比 較 してP28は，FL，KOのいずれにおいてもMAP 2 とproteolipid protein 1 （PLP 1 ）のmRNAの
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イプのP 1 と比較してP28は有意に低下していた。まとめると，PDGFR-βの発現量が最も多いのは，P 1 FL





















































組 織 中 のIL- 6 ，TGF-β 1 ，TNF-αの 発 現 量 はBiosource社 のELISAキット（Rat interleukin ELISA kit，
TGF-β 1  Multispecies ELISA Kit，Rat TNF-α　UltraSensitive ELISA kit，BioSource International，
Inc.，CA）を用いて，使用方法に準じて測定した。内臓脂肪組織の病理学的スコアリングとして，脂肪細
胞の腫大（肥満）の程度を，100倍， 3 視野で測定し， 1 視野あたりの平均脂肪細胞数で評価した。内臓脂
肪壊死・炎症の程度を100倍， 3 視野あたりのマクロファージ集簇（crown like structure; CLS）数として
評価した。また，内臓脂肪のCLSにおけるIL- 6 とTNF-αの発現の有無をそれぞれ抗IL- 6 抗体（goat anti-
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り，当該部を用手で剥離し，ReliaPrep™FFPE gDNA Miniprep Systemを用いてgDNAを抽出した。得ら
れたgDNAを用い，K-ras codon12に対するPCR増幅とMvaⅠでの制限酵素処理によるRestriction restriction 
Fragment fragment Length length Polymorphismpolymorphism（RFLP）と高解像度融解曲線分析（High 







移巣の発生に10ヶ月を，さらに残膵の膵頭部癌の発生にはさらに 3 ヶ月を要していた。第 1 癌と第 2 癌は


















　富山大学医学部医学科 6 年生は，今年度 4 月～ 6 月の12週間の選択制臨床実習を実施した。今回，その選
択制臨床実習を利用して下記の20名が海外で臨床実習を経験してきた。








ベ ト ナ ム：ハノイ小児病院　安川瞳
　今年は，小児科の市田蕗子先生と金兼弘和先生の紹介で 6 名の学生が米国の小児病院で，また脳神経外科




























　小児心臓外科チームは 4 人の専門医と心臓外科志望のレジデント 2 - 3 人そして生徒 2 - 3 人で構成されて
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2014年度　海外実習報告書
中野めぐみ
実習期間　2014年 4 月 ７ 日～ 4 月31日







































































　 4 週間はあっという間に過ぎ去り，気づいたら帰国 3 日前になっていました。最初の 1 週間は生活の仕方






















































たくさんの症例を見学することができました。 1 件の手術に先生が 1 ~ 2 人しか入らないことが印象的でし













































本当に 5 年の ７ 月の時点で当時の自分が選べる選択肢の中からたまたまドイツを選んだのが真実です。（芳
村先生すみません！）
3 ．はっと気づいたのは 2 ，3 月。少し怖気づいたのは 4 月……
　当然ながら，飛行機の手配や実習開始前日のホテルの予約は自分で行わなければいけません。僕は 2 月に
ネット予約を開始しました。一番焦ったのはクレジットカードを持っていなかったということです。 2 月中
はクレジットカードを作ることで終わってしまい， 3 月に入る頃に飛行機のチケットを予約しましたが， 2
か月先のチケットはもうすでに残りが少しという状況でした。
　ドイツ語が必要とは思っていたものの，まだ時間はあると先延ばしにしているうちに 4 月になってしま
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学生研修レポート 109
相原隆充
実習期間：2014年 6 月 2 日~ 6 月2７日（ 4 週間）
実習病院：ルール大学ボッフム校附属
　　　　　ノルトライン＝ヴェストファーレン心臓・糖尿病センター

































































見ることができます。また，小児の先天性心疾患の手術も見学できます。 1 日 2 ， 3 件の手術を見学する事
ができる 1 ヵ月は，心臓外科医を志す私にとって非常に刺激的な毎日でした。
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2014年度海外選択制臨床実習報告書 



































りですが，木曜日以外は朝 ７ 時15分からのカンファレンス（ドイツ語）から始まります。木曜日だけ ７ 時 5
分からレクチャーがあり，スクリーンルームでドイツ語のレクチャーを受けます。そのあと，医師控室に移
り，今日のオペ予定を確認して，自分が見たいオペを見に行きます。 1 日にひとつのオペ室で 3 件，オペ室
は 8 つあり， 1 日で約20件前後のオペが行われているので，毎日見たいと思えるオペが必ずあります。更衣
室はカードキーがないと入室できないので，医師と一緒に行くか，扉をノックして開けてもらいます。ロッ

















ケルン，ドルトムント，フランクフルトへ行くことができました。特に 6 月はドイツの大きなお祭りが 2 つ
もベルリンで開催されるほか，サッカーのワールドカップもあったので，非常に楽しめました。
左：Dr.Michiel Morshuisと　右： 1 か月滞在した民家
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6 ．おわりに
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CCHMCにおける海外研修報告書
野亦悠史
　2014年 4 月 ７ 日～ 4 月25日までの 3 週間，私は 6 年生アドバンス実習の海外プログラムとして小児科の市
田准教授，金兼先生の御縁とご尽力のもと，アメリカ合衆国Ohio州Cincinnatiにある，Cincinnati Children’s 
Hospital Medical Centerにて小児循環器セクションの見学，及び実習をさせていただきました。
　Cincinnati Children’s Hospital Medical Centerは全米屈指の小児病院で，小児循環器セクションだけで 5




ず，看護師の方々が行っていました。また，看護師に対して 1 日 1 回15分程度，術後管理や機械の特性など
のレクチャーをすることで知識の共有を図っているのが印象的でした。





　 3 週目の前半 3 日間は心不全外来でした。先天性の疾患を持ち，心不全を来している患児を専門に見てい
るセクションです。世界で300例しかいないと言われている極めてまれな疾患を 3 例も見ることが出来，大
変 貴 重 な 経 験 が 出 来 ました。大 変 珍 しい 疾 患 を 見 ることができたのはCincinnati Children’s Hospital 







　これらの充実した実習に加え，富山大学の小児科の医師であり，現在はCincinnati Children’s Hospital 
Medical Centerに研究員としていらっしゃる斎藤和義先生にご尽力いただき，私達の 3 週間の研修はより素
晴 らしいものになりました。 斎 藤 先 生 はご 自 身 のラボをみせていただいただけでなく，Cincinnati 
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Boston Children’s Hospital実習報告
山﨑さつき
実習先：Department of Pediatric Cardiology
　　　　Boston Children’s Hospital 
　　　　（アメリカ合衆国マサチューセッツ州）
期間：2014年 6 月 2 日～ 6 月20日
Ⅰ．はじめに













HospitalのPediatric CardiologyのDr. Jane Newburgerに
連絡を取って下さった。同じく実習を希望していた程さん
と私を快く受け入れてくださり，その後実習担当のDr. 
Puja Bankaと何度かメールをやり取りし（Cover Letter〔志望動機書〕とCV〔履歴書〕を書いた）， 6 月に









いただいた。 1 週目､ 2 週目の日程は主に病
棟 回 診，カンファレンスやレクチャーの 参 加













は ７ :00~内科外科合同カンファレンスが行われる。私が驚いたのは症例の多さと（ 1 日に手術 3 件，カテー
テル 3 件ずつある），Cardiac MRIが導入されていたことである。
8 ：00~病棟回診
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のプレゼンとそのフィードバックは毎回必ず聞





































































































































が実習させていただいた循環器部門では，医師数110人，レジデント 5 人，学生 5 人，病棟患者数20人程度，
CICU患者20人程度いました。
4 ．実習内容












































































Rady Children’s Hospital 
3020 Children’s Way, San Diego, CA 92123 U.S.A+ 1  858-576-1700
石坂英理



































Mesaというところにありました。HillcrestのちかくのFashion Vallyというところでは 大 型 モールもあり，
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Rady Children’s Hospital in San Diegoにて実習をさせて頂いて
平田怜子
　この度海外選択実習にて米国のRady Children’s Hospital in San DiegoのCardiologyにて一か月間実習を
させていただきました。

















たのが12月で実習は 4 月でしたので，この約 3 か月に宿，航空券，交通手段，書類手続き，予防接種等の準
備をを行いました。今回の実習では病院と大学と両方へアクセスしやすいように，Hillcrestのstudio819とい
























に来てくれていました。 2 時間半ほどでUiTM Selayang キャンパスに到着しました。UiTMはキャンパス
がいくつかあり，私たちはSelayangとSungai Bulohキャンパスを主に使いましたが，宿舎はSelayangにあ

























at Selayang Campus, Sg Buloh Campus
Week 2 
（19 May 2014）
Primary Care Medicine Posting 




at Sg Buloh Campus














































































を考えるという勉強会を 1 月頃から週に 1 回行っていました。
3 ．実習先情報
　実習先であるUniversiti Teknologi MARAはクアラルンプール郊外にあります。KLIA（空港）からは約
1 時 間 程 です。空 港 までバンでお 迎 えに 来 ていただきました。キャンパスはSelayang，Sungai Buloh，





















○ 3 週目：Pediatrics→この週は医学部 3 年生の方たちと一緒でした






大部屋が 1 つの中に小部屋が 3 室あり，それぞれにトイレ・シャワーがついています。ただしお湯が出る











































































































　UiTMの 医 学 部 のキャンパスには 2 つあります。低 学 年 の 時 のキャンパスと 高 学 年 のキャンパス
（Selayang）の 2 つあります。実習は低学年のキャンパスにある病院，そのそばにある病院，クリニック
で行われました。寮はSelayangキャンパス内にあり，学生と同じ寮に暮らします。 3 LDKで 3 人 1 部屋，





Toyama Medical Journal　Vol. 25　No. 1 　2014142
5 ．実習について
　 1 週 間 ずつ 3 つの 科 を 回 らせていただきました。個 人 で 好 きな 科 を 選 べたのですが，私 は，PCM



















































実習期間：2014年 5 月12日～ 5 月30日
【はじめに】
　私は 6 年次選択制臨床実習の第 2 期にマレーシアのUniversiti Teknologi MARA（UiTM，マラ工科大学）




















































輩より設備は充実した部屋だったようです。部屋は 3 LDK× 2 ， 3 人





















　私たち 6 人は 3 人ずつの 2 グループに分けられ，それぞれ現地の学生の実習グループと行動を共にしまし
た。 私 のグループは 1 週 目「Medicine Posting （のうちCardiology）」 2 週 目「Primary Care Medicine 
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海外選択性臨床実習報告書
田中結香
実習期間：2014年 5 月12日～ 5 月30日










　まずむこうでは英語で症例のプレゼンをすると聞いていたので， 5 年生の 2 月頃から海外実習を選択する







　今回私たちは 6 人で行ったので実習しやすいよう 3 人ずつ 2 グループに分けられていたため，部屋も 2 つ
提供されました。部屋には先輩方が行かれた昨年よりもグレードが上がっていたようで，冷蔵庫やキッチ
ン・食器があり奥には洗濯機もついていました。なので自分たちで調理することも可能でした。シャワーは











































なっている 患 者 さんもたくさんいました。treatment 
roomでは私も足壊疽の患者さんに消毒をして包帯をさ












































Toyama Medical Journal　Vol. 25　No. 1 　2014152
the National Hospital of Pediatricsでの臨床実習の報告
安川　瞳
渡航先：ベトナム，ハノイ
実習病院： the National Hospital of Pediatrics
Department：Cardiology department
Supervisor：Dr. Nguyen Thanh Cong（小児心臓外科）
期間：2014/ 5 / 5 -2014/ 5 /30
実習内容
・小児心臓手術の見学，術野での補助
        ・PDA （Patent ductus arteriosus） closure                                          - 8  cases
           　                                         （PDA ligation                                 - 3  case）
        ・VSD （Ventricular septal defect） patch closure                                  - 6  cases
        ・ASD （Atrial septal defect） closure
・A-P window patch closure
        ・TAPVC （Total anomalous pulmonary venous connection） repair
        ・Tetralogy of Fallot total correction
・心臓カテーテル治療の見学
        ・Amplatzer duct occluder
        ・Amplatzer perimembranous VSD occluder       
・surgical departmentの手術の見学
        ・Choledochal cyst （robotic surgery）
        ・Anorectal malformation
        ・Abdominal cyst
        ・Cystic hygroma
        ・Hypospadiac





・Hai Phong pediatric hospital （province hospital）の訪問
　ベトナム北部で一番の子ども病院であるthe National Hospital of Pediatrics （NHP）にて，小児心臓外科






医のDr. Congにはこんな時期に来た私はunluckyだと言われ続けた。それでも，VSD （Ventricular septal 
defect）やPDA （Patent ductus arteriosus）などを中心に，Dr. Cong曰くのeasy な手術は多数見学するこ
とができた。VSDが最も頻度の高い先天性心疾患であり，医師となったときに必ず出会うであろうことを
考えると，何度も手術で生の心臓を見て目に焼き付けたことは将来の糧となると思う。また，術野に入った
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大きな隔たりがあるようには感じなかった。しかしながら，本報告書で取り上げたVSDや麻疹の例のよう
に，日本では滅多に起こらないことがベトナムでは起きており，まだまだ解決されるべき問題があることが
みえてきた。実習中の手術件数は期待していた数の 4 分の 1 程度であったことは私にとって残念であった
が，麻疹の大流行という状況を経験し，そこから多々考えさせられたという点で，得るものがあった 4 週間
となった。


























　　　　　 1 ．会　　長　　　 1  名
　　　　　 2 ．副 会 長　　　 2  名
　　　　　 3 ．理　　事　　　若干名
　　　　　 4 ．監　　事　　　若干名









　　　　　 3 ．役員の改選は 3 月に行うもものとする。ただし，任期中に欠員を生じた場合は，この限りでない。
第 8 条　本会の事業年度は，年度制による。
































（庶務・集会）　西条寿夫 平成16年 4 月～
（編集委員長）　奥寺　敬 平成1７年 4 月～
理事
庶務・集会　　西条寿夫 平成14年 6 月～
　　　　　　　嶋田　豊 平成16年 4 月～
　　　会計　　山崎光章 平成14年 6 月～
　　　　　　　布施秀樹 平成1７年 4 月～
　　　編集　○奥寺　敬 平成1７年 4 月～
　　　　　　　井村穣二 平成25年 4 月～
　　　　　　　黒田　敏 平成25年 4 月～
　　　　　　　將積日出夫 平成25年 4 月～
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1　Introduction
　Toyama Medical Journal is the official publication of 
the University of Toyama medical association.
2　Types of papers
　Reviews, original articles, case series, case reports, 
short communications and meeting abstracts held in 
and around Toyama prefecture will be considered.
3　Formatting guidelines
a) Article structure
　Papers should be set out in the following order: title 
page, abstracts, text, references, tables and figures. The 
data and two sets of printed manuscripts must be sent 
to the editorial office.  Manuscripts which are written 
by non-native English writer must be proofread by 
language services and required to provide a certificate 
in proofreading. 
b) Format of printed out 
　Manuscripts should be written by use of 
wordprocessing software. Text should be written in 
double-spaced. The number of tables and figures is up 
to five in total.
c) Title page
　The title page must have the category of the article 
(for example “original article”), the complete title of the 
paper, name(s) of author(s), affiliation(s) , key words(up 
to five), running title, number of pages of text, number 
of tables and figures, order of reprints (50 copies in a 
unit).
d) Abstract
　Abstract must be written in 200 words and printed in 
double-spaced.
e) Text
　Authors should use the following subheadings to 
divide the sections of their manuscript: Introduction, 
Materials and Methods, Results and Discussion. Heading 
in the text must be written as follows.
I, II, ……,  A, B, ……,  1, 2, ……,  a, b, ……, 
(1), (2), …….
　Acknowledgments should be placed at the last section 
of the text.
f) Scientific names
　Scientific names should be underlined.
g) Abbreviations and units
　All abbreviations should be fully explained at their 
first occurrence in the text. 
　All measurements should be expressed in metric 
units, SI units.
[Length] m, cm, mm, μm, nm, Å
[Weight] kg, g, mg, μg
[Square] m2, mm2
[Cubic measure] m3, cm3 , mm3
[Volume] l, ml, μl
[Mole number and concentration] mol, mmol, μmol, 
nmol, pmol, M(mol/L), Eq, N(normal), %
[Time] d, h, min, s, ms, μs
[Temperature] ℃
[Pressure] mmHg, mber
[Electricity] V(volt), A(ampere), Hz(cycles/sec)
[Radiation] Ci, cpm, r
[Optical isomer] d-, l-, dll
[Administration] iv, ip, im, sc, po
[Statistics] SD, SEM
[Others] g(gravity), LD50, ED50 
h) Reference
　In the text, references should be cited using 
superscript Arabic numerals in the order in which they 
appear. If the work has equal to or more than five 
authors, list the first three authors followed by et al. 
The reference list should be written following the 
examples given below. Journal names should be 
abbreviated according to INDEX MEDICUS (http://
www2.bg .am.poznan .p l/czasop isma/medicus .
php?lang=eng).
Journal articles
1)  Kimimura K., Takatsu T. and Ahmed A.: A survey 
of mosquitoes in Karachi area, J Pak Med Assoc. 
36: 181-188, 1986.
Book
2)  Nakata T. and Katayama T.: Changes in human 
adrenal catecholamines with age. In: Urology 
(Jardan A. ed.)  : 404-406. International B’Urologie, 
Paris, 1986. 
i) Figures and tables
　All figures and tables should be cited in text in 
Toyama Medical Journal
Instructions for Authors
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consecutive numerical order. The printout of them 
should be attached in order after the last page of the 
text. Each table and figure should not extend beyond 
one page.
4　Peer review and acceptance
　Every article has been peer reviewed. Acceptances 
are decided by editorial board of the University of 
Toyama medical association.
5　Proofreading
　The purpose of the proof is to check for typesetting 
or conversion errors. Substantial changes in content are 
not allowed without the approval of the editor
6　Publication charges and reprints
　Page charges: ¥ 5,000 for a page up to six pages, ¥ 
9,000 for a page from seven to ten pages. When the 
paper has more than 10 pages, the charges of reprints 
(included postage charges) are informed through a 
charge sheet. Color prints are available for extra 
charges.
7　Submission of manuscripts
　Authors should send the manuscript files and prints 
to the Editorial Office of Toyama Medical Journal.
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3 　執 筆 規 定　以下の規定に従う。























































文 ではet al．）とする。とくに 句 読 点 に 注 意 す
る。　
　　和文原著文献






マリハビリテーション 講 習 会 実 行 委 員 会
編）：209−225．金原出版，東京，1986．
英文原著文献
3 ）Kamimura K., Takasu T. and Ahmed A. :　
A survey of mosquitoes in Karachi area, J 
Pak Med Ass. 36 : 181−188, 1986.
英文単行本
4 ）Nakata T. and Katayama T. : Changes in 
human adrenal catecholamines with age. In 
:  Urology ( Jardan A .  ed. )  :  404−406. 



















6 　掲載料，別刷費用　本文・図表を含め刷り上り 6 頁








 1988年 1 月 5 日制定
 1994年 3 月22日改訂
 1996年 2 月 9 日改訂
 2008年10月 8 日改訂
さまるものとし，本文とは別にまとめ，Table 1
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